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A B S T R A C T
It is well established that a family of dual-speciﬁcity MAP kinase phosphatases (MKPs) play key roles in the
regulated dephosphorylation and inactivation of MAP kinase isoforms in mammalian cells and tissues. MKPs
provide a mechanism of spatiotemporal feedback control of these key signalling pathways, but can also mediate
crosstalk between distinct MAP kinase cascades and facilitate interactions between MAP kinase pathways and
other key signalling modules. As our knowledge of the regulation, substrate speciﬁcity and catalytic mechanisms
of MKPs has matured, more recent work using genetic models has revealed key physiological functions for MKPs
and also uncovered potentially important roles in regulating the pathophysiological outcome of signalling with
relevance to human diseases. These include cancer, diabetes, inﬂammatory and neurodegenerative disorders. It
is hoped that this understanding will reveal novel therapeutic targets and biomarkers for disease, thus con-
tributing to more eﬀective diagnosis and treatment for these debilitating and often fatal conditions.
1. Introduction
Mammalian dual-speciﬁcity MAP kinase (MAPK) phosphatases (MKPs)
comprise a subfamily of 10 catalytically active enzymes with a conserved
domain structure. This consists of an amino-terminal non-catalytic domain
and a carboxyl-terminal catalytic domain. The former contains the kinase
interaction motif (KIM), which determines the speciﬁc binding and thus
substrate selectivity of the MKP for the diﬀerent MAP kinase isoforms and
can also contain nuclear localisation (NLS) or export (NES) signals, which
determine the subcellular localisation of certain MKPs. The catalytic domain
carries the highly conserved active site consensus sequence (HCX5R) that is
characteristic of the larger protein tyrosine phosphatase (PTPase) super-
family. The regulation, structure, catalytic mechanism and substrate se-
lectivity of the MKPs have been extensively reviewed [1–6]. Brieﬂy, the 10
enzymes can be divided into three subgroups based on amino acid sequence
homology, subcellular localisation and substrate speciﬁcity. These are the
inducible nuclear MKPs, comprising DUSP1/MKP-1, DUSP2, DUSP4/MKP-2
and DUSP5, the cytoplasmic, extracellular-signal regulated kinase (ERK)
-speciﬁc MKPs DUSP6/MKP-3, DUSP7/MKP-X and DUSP9/MKP-4 and a
group of three MKPs DUSP8, DUSP10/MKP-5 and DUSP16/MKP-7 that are
found in both the cytoplasm and cell nucleus and are relatively selective in
their ability to dephosphorylate the p38 and c-Jun amino terminal kinases
(JNKs), having little or no activity towards the classical extracellular signal-
regulated kinase (ERK) MAPKs (Fig. 1). Key features and characteristics of
each of the 10 MKPs are also summarised (Table 1).
Our understanding of the physiological and pathophysiological roles
for the MKPs has largely been driven by the generation of genetically
engineered mouse (GEM) models in which individual MKPs have been
deleted, either unconditionally, or in a tissue speciﬁc manner. This
work, combined with studies in other model organisms, cell lines and
observations in human cells and tissues has gradually revealed that
MKPs play fundamental roles in the regulation of signalling events as-
sociated with normal development and homeostasis, but can also
modulate a wide range of pathophysiological signalling outcomes with
relevance to human disease. In this review we will detail the current
level of understanding for each of the MKPs in turn, highlighting recent
advances and future perspectives in the ﬁeld.
2. The inducible nuclear MKPs
2.1. DUSP1/MKP-1
DUSP1/MKP-1 was the ﬁrst of the dual-speciﬁcity MKPs to be
characterised and was initially discovered as a growth factor or stress-
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inducible gene encoding a nuclear protein with homology to VH1, the
prototypic dual-speciﬁcity protein phosphatase encoded by vaccinia
virus [7,8]. Initially characterised as a phosphatase able to speciﬁcally
dephosphorylate the threonine and tyrosine residues of the signature T-
E-Y motif within the activation loop of the classical MAPK ERK2 in vitro
and in vivo [9,10] it was later realised that DUSP1/MKP-1 was capable
of dephosphorylating all three major classes of MAPK with a distinct
preference for the JNK isoforms followed by p38α and ERK1/2 MAPKs
[11–15]. DUSP1/MKP-1 was also the ﬁrst gene encoding an MKP to be
deleted in the mouse, where no phenotype was initially reported with
respect to development, fertility or lifespan and no evidence for de-
regulated ERK signalling was found in DUSP1−/− mouse embryo ﬁ-
broblasts (MEFs) [16]. The failure to detect changes in MAPK activity in
cells lacking DUSP1/MKP-1 was probably due to an initial focus on the
ERK1/2 pathway. Subsequent work in MEFs clearly showed that loss of
DUSP1/MKP-1 caused a signiﬁcant increase in the activities of the
stress-induced JNK and p38 MAPKs and revealed that MEFs lacking
MKP-1 are acutely sensitive to JNK-mediated apoptosis in response to a
wide variety of cellular stresses including UV-radiation, ionising ra-
diation, hydrogen peroxide, anisomycin and cisplatin [17–21]. Further
experiments conducted using DUSP1−/− mice quickly led to the rea-
lisation that this phosphatase regulates a number of physiological and
pathophysiological processes including immunity, metabolic home-
ostasis, cellular responses to anticancer drugs, muscle regeneration, and
neuronal function.
2.1.1. DUSP1/MKP-1 in innate and adaptive immunity
Given the wide range of roles that MAPKs perform in the develop-
ment and function of cells of the immune system [22–24] it was per-
haps no surprise that amongst the ﬁrst phenotypes detected in DUSP1−/
− mice was a failure to regulate stress-activated JNK and p38 signalling
in macrophages and dendritic cells (Fig. 2: Table 2). These cells are key
mediators of the innate immune response in which the p38 and JNK
MAPKs lie downstream of the toll-like receptors (TLRs), which are ac-
tivated by a wide variety of pathogen-derived stimuli and act to reg-
ulate the expression of both pro and anti-inﬂammatory cytokines and
chemokines [22]. Several groups demonstrated that loss of DUSP1/
MKP-1 led to elevated JNK and p38 activities in macrophages exposed
to the bacterial endotoxin lipopolysaccharide (LPS) [25–28]. This led to
an initial increase in the expression of pro-inﬂammatory cytokines such
as tumour necrosis factor alpha (TNFα), interleukin-6 (IL-6), inter-
leukin-12 (IL-12) and interferon-gamma (IFN-γ) while, at later times,
levels of the anti-inﬂammatory mediator interleukin-10 (IL-10) were
increased [25]. These cellular eﬀects were accompanied by
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Fig. 1. Schematic showing the domain structures of the three groups of dual-speciﬁcity MAP kinase phosphatases. A. The nuclear inducible MKPs. B. The cytoplasmic ERK-
speciﬁc MKPs and C. the JNK/p38-speciﬁc MKPs. In addition to the amino-terminal non-catalytic domain and the PTPase active site, other key features and sequence
motifs are indicated.
Table 1
Classiﬁcation and properties of the mammalian dual speciﬁcity MAP kinase phosphatases.
Group Gene/MKP Subcellular localisation Substrate speciﬁcity Mouse models References
Nuclear, inducible MKPs DUSP1/MKP-1 Nuclear JNK, p38 > ERK UC, C [16,56]
DUSP2 Nuclear ERK, JNK UC [86,87]
DUSP4/MKP-2 Nuclear ERK, JNK > p38 UC [97]
DUSP5 Nuclear ERK UC [128]
Cytoplasmic ERK-selective MKPs DUSP6/MKP-3 Cytoplasmic ERK UC [149]
DUSP7/MKP-X Cytoplasmic ERK UC* IMPC
DUSP9/MKP-4 Cytoplasmic ERK > p38 UCǂ, C [175,183]
JNK/p38-selective MKPs DUSP8 Cytoplasmic/nuclear JNK, p38 N/A
DUSP10/MKP-5 Cytoplasmic/nuclear JNK, p38 UC [185]
DUSP16/MKP-7 Cytoplasmic/nuclear JNK, p38 UCǂ [195,196]
UC, unconditional. C, conditional. *, infertile. ǂ, embryonic lethal. IMPC, International Mouse Phenotyping Consortium.
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pathological changes such as inﬂammatory tissue inﬁltration, hypo-
tension and multiple organ failure, all of which are markers of the se-
vere septic shock and increased mortality observed in LPS-injected
DUSP1−/− mice when compared to wild type controls.
With respect to the above changes in cytokine expression, the reg-
ulation of gene transcription by MAPK-regulated transcription factors
such as activator protein-1 (AP1), activating transcription factor 1
(ATF-1) and cAMP response element binding protein (CREB) by
DUSP1/MKP-1 was an early focus [25,29]. However, a major me-
chanism by which cytokine expression is controlled is via changes in
mRNA stability and recent studies have revealed that DUSP1/MKP-1
modulates cytokine mRNA levels by suppressing the p38 driven MAPK-
activated protein kinase 2 (MK2)-dependent phosphorylation of the
mRNA destabilising protein tristetraprolin (TTP) [30]. TTP, which re-
cognizes adenosine/uridine-rich elements (AREs) in the 3′ untranslated
regions (UTRs) of cytokine mRNAs and recruits components of the
cellular mRNA degradation machinery is phosphorylated by MK-2 on
two sites (Ser52 and 178), which leads to both inactivation and stabi-
lisation of TTP [31]. Thus, loss of DUSP1/MKP-1, by promoting p38-
MK2-driven phosphorylation of TTP, favours TTP inactivation and cy-
tokine mRNA stabilisation. In an elegant series of experiments, Smallie
et al., combined deletion of DUSP1/MKP-1 with a homozygous knock-in
mutant in which the MK2-dependent phosphorylation sites within TTP
are ablated and demonstrated that in bone marrow-derived macro-
phages (BMDMs) derived from the double mutant mice the elevated
cytokine mRNA and protein levels seen on deletion of DUSP1/MKP-1
alone was largely prevented. A similar reversal in the elevated serum
levels of cytokines seen in LPS-injected DUSP1−/− mice was also ob-
served in the double mutant animals and microarray experiments per-
formed using LPS-treated BMDMs, indicate that DUSP1/MKP-1 reg-
ulates more than half of the genome-wide response to LPS, either
wholly or partly via the phosphorylation of TTP [30]. A similar ap-
proach revealed that production of interferon beta (IFNβ) in response to
TLR activation is also mediated in part by DUSP1/MKP-1-mediated
regulation of TTP, but that in the early phase of the response DUSP1/
MKP-1 regulates IFNβ transcription via JNK-mediated phosphorylation
of c-jun, which binds to the IFNβ promoter [32].
Taken together, this work demonstrates that TLR mediated expression
of DUSP1/MKP-1 is a key component of a pathway, which acts through
regulation of MAPK-dependent transcription factors and TTP to negatively
regulate pathological inﬂammatory responses, to engage the “oﬀ phase” of
macrophage-mediated responses to pro-inﬂammatory stimuli and promote
the resolution of inﬂammation. As such, any defects in this pathway would
be expected to impede the latter process and contribute to a range of
chronic inﬂammatory diseases, making the DUSP1/MKP-1-p38-MK2 sig-
nalling axis a prime candidate for therapeutic intervention.
p-p38
p-JNK
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Dendritic cells
p-p38
Th1 response 
Th17 response 
Cytokine production
(TNFα, IL-12, IFN-γ, IL-10)
Fig. 2. DUSP1/MKP-1 in innate immunity. Schematic showing the regulation of
MAP kinase activities in cells of the innate immune system by DUSP1/MKP-1
and the consequences of genetic deletion of this MKP on the physiological re-
sponses of these cell populations. For details see text.
Table 2
Immunological phenotypes of MKP KO mice.
Group Gene/MKP Immunological phenotypes of MKP KO mice References
Nuclear, inducible MKPs DUSP1/MKP-1 Increased pro-inﬂammatory cytokine production & innate immune response LPS challenge. [25]
Impaired resolution of inﬂammation. [30]
Decreased adaptive immune response & viral clearance. [33]
Protection from autoimmune encephalitis (EAE). [33]
Increased sensitivity to bacterial infections. [35]
Exacerbates inﬂammatory phenotypes including: colitis, anaphylaxis and psoriasis. [40–42]
DUSP2 Protection from experimentally-induced arthritis. [86]
Decreased macrophage cytokine expression & mast cell survival. [86]
Increased susceptibility to DSS-induced model of intestinal inﬂammation. [87]
Altered T-cell balance, via the promotion of Th17 diﬀerentiation and inhibition of Treg generation. [87]
DUSP4/MKP-2 Increased susceptibility to Leishmania mexicana, Leishmania donovani & Toxoplasma gondii infection. [97–99]
Resistant to LPS-induced endotoxic shock. [100]
Increased CD4+ T-cell proliferation. [101]
Protection from autoimmune encephalitis (EAE). [102]
DUSP5 Negatively regulates Il-33 mediated eosinophil survival. [119]
Resistant to helminth infection, due to enhanced eosinophil activity. [119]
Regulates CD8+ populations in response to LCMV infection. [120]
Cytoplasmic ERK-selective MKPs DUSP6/MKP-3 Exacerbates intestinal colitis. [150]
Decreased CD4+ T-cell proliferation, altered T-cell polarisation & impaired Treg function. [150]
DUSP7/MKP-X N/A
DUSP9/MKP-4 N/A
JNK/p38-selective MKPs DUSP8 N/A
DUSP10/MKP-5 Impaired T cell expansion, but enhanced priming of T-cells by APCs. [185]
Protection from autoimmune encephalitis (EAE). [185]
Increased cytokine and ROS production in macrophages, neutrophils and T cells. [187]
Protection from DSS-induced intestinal inﬂammation. [191]
DUSP16/MKP-7 Impaired GM-CSF-driven proliferation of bone marrow progenitors. [195]
Increased CD4+ T-cell proliferation & a reduced Th17 cell population. [196]
Protection from autoimmune encephalitis (EAE). [196]
LCMV, lymphocytic choriomeningitis virus. DSS, dextran sodium sulfate.
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While innate immunity comprises an acute, non-speciﬁc response to
foreign antigens, adaptive or acquired immunity is highly speciﬁc to a
particular antigenic stimulus and comprises a network of specialized,
immune cells and processes that either eliminate pathogens or prevent
their growth. In addition, by generating immunological memory, this
response also provides long-lasting immunity against infection, which is
the basis of vaccination, while an abnormal or maladaptive response
can result in autoimmune disease. The workhorses of the system are the
B and T lymphocytes, which mediate humoral (antibody-mediated)
immunity and cell-mediated (cytotoxic or eﬀector cell-mediated) re-
sponses. Despite the key role for ERK signalling in thymocytes and the
observation that DUSP1/MKP-1 is expressed at varying levels during T-
cell development, mice lacking DUSP1/MKP-1 do not present with
abnormalities in this process and the ratio of CD4+ to CD8+ T-cells
following thymic maturation is in the normal range [33]. This possibly
reﬂects either redundancy amongst ERK-speciﬁc phosphatases or the
fact that ERK is not the preferred target for DUSP1/MKP-1.
However, in mature CD4+ T cells, loss of DUSP1/MKP-1 seems to
impact T cell function with decreased activation and proliferation fol-
lowing exposure to phorbol 12-myristate 13-acetate (PMA) and iono-
mycin and increased levels of JNK signalling [33]. Furthermore, both
CD4+ and CD8+ T cells lacking DUSP1/MKP-1 showed reduced pro-
liferation and interleukin-2 (IL-2) production after exposure to anti-CD3
antibody to mimic T cell receptor activation, either alone or in com-
bination with anti-CD28. This lack of proliferation correlated with a
failure to accumulate nuclear factor of activated T cells c1 (NFATc1) in
the cell nucleus and, as this process is negatively regulated by JNK
signalling, most probably reﬂects a failure to restrain JNK activity in
these cells [33]. Consistent with this, re-stimulation of activated
DUSP1−/− CD4+ T cells with anti-CD3 also caused an increase in JNK-
dependent activation-induced cell death (AICD). The diﬀerentiation of
eﬀector T cell lineages was also aﬀected by deletion of DUSP1/MKP-1
with naïve DUSP1−/− CD4+ T cells showing deﬁcits in eﬀector cyto-
kine producing type-1 helper (Th1) and pro-inﬂammatory type-17
helper (Th17) cell diﬀerentiation and function, while in naïve CD8+ T
cells DUSP1/MKP-1 deﬁciency resulted in lower production of the
CD8+ T cell eﬀector cytokines IFN-γ and TNFα [33]. Finally, DUSP1/
MKP-1was found to be required for anti-inﬂuenza T cell responses in
infected mice with infected DUSP1−/− animals showing defective in-
ﬂuenza virus-speciﬁc CD4+ and CD8+ T cell responses and clear signs
of impaired viral clearance. In contrast, mice lacking DUSP1/MKP-1
were protected from experimentally induced autoimmune encephalitis
(EAE) following injection of myelin oligodendrocyte glycoprotein
peptide (MOG35–55). This resulted from an intrinsic defect in MKP-1 KO
CD4+ T cells, which showed reduced production of IL-17 and IFNγ and
demonstrates a key role for DUSP1/MKP-1 in mediating autoreactive
CD4+ T cell responses in vivo [33].
As well as performing key functions in innate immunity, dendritic
cells form a bridge between innate and adaptive immune responses by
acting as antigen presenting cells for the priming of both CD4+ T
helper (Th) and CD8+ cytotoxic T lymphocytes (Tc) [34]. As well as
aﬀecting the function of these T cell subsets, it turns out that DUSP1/
MKP-1 also plays a key role in facilitating this crosstalk. Huang et al.
[35] used a model in which the immune system in lethally irradiated
mice was reconstituted with a mix of bone marrow from DUSP1−/
−/Rag1−/− and WT mice (5:1 ratio) and compared with mice recon-
stituted using DUSP1+/+/Rag1−/− and WT (5:1 ratio) bone marrow.
In both cohorts the T cells were derived from the WT marrow (Rag1−/−
bone marrow cannot generate mature T and B cells) and thus expressed
DUSP1/MKP-1 while the cells of the innate immune system were either
null or WT for DUSP1/MKP-1. Using two mouse infection models, the
Listeria monocytogenes (Th1 biased model) and Candida albicans (Th17
biased model), they found that dendritic cells lacking DUSP1/MKP-1
exhibited reduced IL-12 production and attenuated IFNγ expression and
Th1 responses. In contrast, the production of IL-6 by dendritic cells
lacking DUSP1/MKP-1 was enhanced and this resulted in an
exaggerated Th17 response. In addition, DUSP1/MKP-1 suppressed the
release of transforming growth factor β2 (TGFβ2) by dendritic cells,
thus inhibiting the development of inducible regulatory T cells (Treg).
At the biochemical level, these altered responses were mediated by
increased p38 MAPK activity in dendritic cells lacking DUSP1/MKP-1.
In conclusion this work clearly shows that the activity of DUSP1/MKP-1
in the dendritic cells of the innate immune system is a critical regulator
of signals that dictate the course of adaptive immune responses at the
immunological synapse [35].
One interesting observation arising from these studies of DUSP1/
MKP-1 in innate and adaptive immunity is that whereas DUSP1/MKP-1
mainly targets p38 MAPK in macrophages and dendritic cells, the T cell
eﬀects of DUSP1/MKP-1 loss seem to be mediated predominantly by
increased JNK activity. This suggests that there is cell type speciﬁcity
with respect to DUSP1/MKP-1 activity towards diﬀerent MAPK iso-
forms. The mechanism by which this might be achieved is unclear, but
may be related to post-translational modiﬁcation. DUSP1/MKP-1 is
phosphorylated and this is known to modulate its stability [36,37].
More recently, it was shown that p300 histone acetylase-mediated
acetylation of lysine 57, which lies just C-terminal of the KIM within the
amino terminal domain of DUSP1/MKP-1, reinforces its interaction
with and ability to dephosphorylate p38 MAPK [38]. This can be op-
posed by a subset of speciﬁc histone deacetylases (HDACs 1–3) in
mouse macrophages [39], suggesting one possible mechanism by which
the canonical substrate selectivity of DUSP1/MKP-1 might be regulated
in a cell type speciﬁc manner.
Finally, given its key role as a critical regulator of innate and
adaptive immunity (Table 2), loss of DUSP1/MKP-1 was also found to
exacerbate a range of inﬂammatory phenotypes in mouse models in-
cluding experimental colitis [40], anaphylaxis [41] and psoriasis [42],
However, for reasons as yet unclear, loss of DUSP1/MKP-1 did not
sensitize mice to the development of spontaneous age-dependent os-
teoarthritis, despite the involvement of an inﬂammatory process and
mediators such as TNFα and interleukin-1β in this disease [43].
DUSP1/MKP-1 is also directly targeted by a range of immune mod-
ulators. Enhanced expression of DUSP1/MKP-1 underpins, at least in
part, the anti-inﬂammatory activity of glucocorticoids [44,45] and is
also observed in response to vitamin D [46] and transforming growth
factor-beta (TGFβ) [47] both of which are anti-inﬂammatory. In con-
trast, pro-inﬂammatory stimuli such as IFN-γ and interleukin-17A (IL-
17A) suppress DUSP1/MKP-1 expression and thus increase signalling
through the p38 and JNK MAPK pathways [48,49].
2.1.2. DUSP1/MKP-1 in metabolic homeostasis
The ﬁrst indication that DUSP1/MKP-1 might play a role in reg-
ulating metabolic homeostasis came with the ﬁnding that DUSP1−/−
mice were resistant to diet-induced obesity (Fig. 3) and that this re-
ﬂected a higher level of energy expenditure, but not overall activity in
the null mice [50]. Surprisingly, despite remaining lean on a high-fat
diet (HFD), DUSP1−/− mice did become glucose intolerant (as would
wild type animals), while still being protected from hepatic steatosis.
This phenotype correlated with increased levels of JNK, p38 and ERK
activity in insulin responsive tissues. However, DUSP1−/− mice did not
show abnormalities in insulin signalling or glucose homeostasis, despite
an established role for JNK signalling in promoting insulin resistance
[51]. This apparent contradiction was possibly due to the ﬁnding that
loss of DUSP1/MKP-1 aﬀects nuclear rather than cytoplasmic JNK ac-
tivity and that the latter is responsible for JNK-dependent abnormalities
in the response to insulin [50].
Subsequent work has revealed mechanistic aspects of the DUSP1−/
− metabolic phenotype. Firstly, mice lacking DUSP1/MKP-1 are pro-
tected from the loss of oxidative (slow-twitch) myoﬁbers in skeletal
muscle. The overall eﬀect of this is to favour oxidative over glycolytic
metabolism and, because the latter consumes less energy, to protect
against diet-induced obesity [52]. This eﬀect seems to be secondary to
increased p38 MAPK-mediated phosphorylation and stabilisation of
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peroxisome proliferator-activated receptor-gamma coactivator 1α
(PGC-1α) thus increasing its activity as a regulator of mitochondrial
biogenesis and energy expenditure. Experiments in which grossly obese
leptin-resistant (db/db) mice were crossed with DUSP1−/− animals
revealed that loss of DUSP1/MKP-1 protected against hepatic steatosis.
By increasing MAPK-dependent phosphorylation of peroxisome pro-
liferator-activated receptor-γ (PPARγ) at a site (Ser112) that negatively
regulates its activity, loss of DUSP1/MKP-1 prevents the PPARγ-de-
pendent expression of lipogenic genes, thus reducing lipid droplet for-
mation in hepatocytes [53].
While this work sheds some light of the functions of DUSP1/MKP-1
in metabolic homeostasis a severe limitation of these studies is the use
of a whole body DUSP1/MKP-1 knockout. Metabolic control is complex
and subject to both central and peripheral regulation [54]. Further-
more, diet-induced obesity has an inﬂammatory component [55] and
the role(s) of DUSP1/MKP-1 in regulating immune responses may also
be a confounding factor. To begin to address this, a conditional
DUSP1ﬂ/ﬂ mouse has now been employed to study the metabolic eﬀects
of DUSP1/MKP-1 deletion in speciﬁc tissues.
Liver speciﬁc knockout of DUSP1/MKP-1 (MKP-1-LKO) using al-
bumin-Cre (Alb-Cre) resulted in increased hepatic JNK and p38 acti-
vation. However, unlike DUSP1−/−mice MKP-1-LKO animals exhibited
increased adiposity, fasting hyperglycaemia and hyperinsulinemia on a
normal chow diet, indicating that hepatic DUSP1/MKP-1 regulates
glucose homeostasis (Fig. 3). This was conﬁrmed in subsequent ex-
periments using hyperinsulinemic-euglycemic clamps, which demon-
strated that MKP-1-LKO mice were hyperglycaemic, glucose intolerant
and develop hepatic insulin resistance [56]. While DUSP1−/− mice
were resistant to HFD-induced obesity MKP-1-LKO mice were more
susceptible, but were still protected against hepatic steatosis. Further-
more, unlike DUSP1−/− mice, they showed decreased energy ex-
penditure [56]. Mechanistically, the eﬀects of DUSP1/MKP-1 deletion
on glucose metabolism were found to be secondary to increased hepatic
p38 and JNK mediated transcription of gluconeogenic genes, increased
p38-dependent phosphorylation of cyclic AMP responsive element
binding protein (CREB), which promotes gluconeogenesis through
PGC1/PPARγ and decreased activation of Signal Transducer and Acti-
vator of Transcription 3 (STAT3), a negative regulator of gluconeo-
genesis [56]. The latter eﬀect is probably an indirect result of the lower
circulating levels of IL-6 in MKP-1-LKO mice, as this metabolic cytokine
is a potent inducer of Janus kinase (JAK)-STAT signalling. Finally, the
decreased energy expenditure observed in MKP-1-LKO mice may be
related to reduced levels of IL-6 and ﬁbroblast growth factor 21
(FGF21). Both factors promote energy expenditure, insulin sensitivity,
fatty acid oxidation, and weight loss and their reduction would be ex-
pected to impair skeletal muscle oxidative capacity and thus increase
susceptibility to diet-induced obesity [56].
Skeletal muscle plays a major role in the regulation of glucose
metabolism and metabolic homeostasis. Following on from the liver-
speciﬁc deletion of DUSP1/MKP-1, the eﬀects of skeletal muscle speciﬁc
loss of this phosphatase (MKP-1-MKO), using human α-skeletal actin
(HSA-Cre), have now been studied. MKP-1-MKO mice show increased
levels of p38 and JNK signalling in skeletal muscle and are signiﬁcantly
protected from HFD-induced weight gain (Fig. 3). As was the case in the
MKP1−/− mice, the failure to gain weight was secondary to enhanced
energy expenditure when compared with MKP-1ﬂ/ﬂ controls and no
diﬀerences in either food intake, or activity between the two genotypes
was observed [57]. Interestingly, MKP-1-MKO mice were also resistant
to hepatic steatosis, which was consistent with lower levels of hepatic
PPARγ and sterol regulatory element-binding protein 1c (SREBP-1c)
expression. However, no changes in either p38 or JNK activity were
detected in liver tissue. Glucose (GTT) and insulin tolerance (ITT) tests
revealed that MKP-1MKO mice on a HFD produced lower levels of
circulating insulin and were insulin sensitive, indicating that they are
protected from the development of insulin resistance. Biochemically, an
unexpected role for increased PI3-kinase-Akt signalling resulting from
microRNA-21 (miR-21) dependent down-regulation of phosphatase and
tensin homolog (PTEN) in MPK-1-MKO was uncovered and this could
contribute to the increased insulin sensitivity observed in MKP-1-MKO
mice. Finally, consistent with the results of whole body deletion of
DUSP1/MKP-1
• Increased JNK, p38 and ERK activity
in insulin responsive tissues
• High energy expenditure
• Resistant to HFD-induced obesity
• Do not develop hepatic steatosis
• Normal glucose homeostasis
• Increased hepatic JNK and p38 activity
• Sensitive to HFD-induced obesity
• Decreased energy expenditure
• Hyperglycaemia and hyperinsulinemia
• Increased gluconeogenesis
• Increased muscle JNK and p38 activity
• Resistant to HFD-induced obesity
• Increased energy expenditure
• Resistant to hepatic steatosis
• Insulin sensitive on HFD
Whole Body KO
Skeletal Muscle KOLiver-Specific KO
Fig. 3. DUSP1/MKP-1 in metabolic homeostasis. Schematic showing the eﬀects of either unconditional, or tissue-speciﬁc, deletion of DUSP1/MKP-1 on metabolic
homeostasis. For details see text.
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DUSP1/MKP-1, the increased energy expenditure observed in MKP-1-
MKO mice was secondary to an increase in the proportion of oxidative
myoﬁbers and was reﬂected in enhanced oxidative capacity and mi-
tochondrial function in skeletal muscle [57].
Taken together, these results begin to unravel some of the com-
plexity and tissue speciﬁc interplay of DUSP1/MKP-1 action in the
regulation of metabolic homeostasis (Fig. 3; Table 3) and also empha-
sise the importance of compartmentalised nuclear regulation of p38 and
JNK activities in mediating the phenotypes observed. The observation
that DUSP1/MKP-1 is up-regulated in insulin-responsive tissues in re-
sponse to a HFD in mice and also in obese humans indicates that it
forms part of a key stress response that leads to decreased energy ex-
penditure in skeletal muscle, thus contributing to weight gain and may
also mediate at least some of the adverse consequences of this disease,
including abnormalities in glucose metabolism and hepatosteatosis. The
further use of conditional DUSP1/MKP-1 ablation will reveal the re-
lative importance of MAPK regulation in distinct tissues by this phos-
phatase in energy homeostasis and, from the information gathered so
far, MKP-1/DUSP1 continues to be a potential pharmacological target
for the treatment of metabolic disease.
2.1.3. DUSP1/MKP-1 in cancer
Given the central importance of deregulated MAPK signalling in the
initiation and progression of human cancers it is no great surprise that
the involvement of MKPs in regulating various aspects of the cancer
phenotype has been of widespread interest [58–60]. Disappointingly,
given that DUSP1/MKP-1 was both the ﬁrst MKP to be discovered and
also the ﬁrst to be deleted from the mouse genome, there are currently
no published studies in which DUSP1/MKP-1 has been directly im-
plicated in either tumour initiation or progression. It is hoped that the
recent development of the conditional DUSP1/MKP-1 mouse (see
2.1.2.) will facilitate deﬁnitive experiments, particularly as this model
avoids the potentially confounding eﬀects of the immune and in-
ﬂammatory abnormalities seen when DUSP1/MKP-1 is knocked out
globally.
In contrast, over the 25 or so years since DUSP1/MKP-1 and its role
in regulating MAP kinase signalling were discovered, there have been
numerous publications reporting either increased or reduced expression
of DUSP1/MKP-1 in a wide range of human tumours including breast,
pancreas, gastric, ovary, lung, skin and prostate (Table 4). In addition, a
number of studies have relied on ectopic overexpression of DUSP1/
MKP-1 in normal and cancer cell lines to study its possible role in
modulating oncogenic signalling. These studies have been extensively
reviewed elsewhere [60] and as they have often yielded equivocal or
even contradictory information regarding the role of DUSP1/MKP-1 in
cancer, it is not proposed to list or discuss them further here.
One aspect of cancer biology in which DUSP1/MKP-1 does appear to
play an important role is in the response of normal and cancer cells to a
range of chemical and physical insults including modalities used in
cancer chemotherapy (Table 4). Soon after it became clear that the p38
and JNK MAPKs were the preferred substrates for DUSP1/MKP-1, it was
observed that the overexpression of this phosphatase enhanced cellular
resistance to both UV-radiation and the chemotherapeutic drug cis-
platin and that this was related to the suppression of JNK-mediated
apoptosis [61,62]. That DUSP1/MKP-1 played a crucial role in mod-
ulating sensitivity to these insults was conﬁrmed when MEFs derived
from DUSP1−/− mice were found to be sensitive to UV-radiation, cis-
platin, hydrogen peroxide and anisomycin [17–20]. In normal cells,
DUSP1/MKP-1 expression is induced by UV and cisplatin via activation
of p38 MAPK, whereas it is the suppression of JNK activity by DUSP1/
MKP-1 that modulates cell death. This indicates that DUSP1/MKP-1
mediated crosstalk between these two distinct MAPK pathways reg-
ulates cellular sensitivity [20].
Thus it is likely that elevated expression of DUSP1/MKP-1 in tu-
mours can mediate chemoresistance and this is supported by studies in
non-small cell lung cancer (NSCLC) where overexpression of DUSP1/
MKP-1 is observed and patients become resistant to treatment with
cisplatin. In NSCLC cancer cell lines where DUSP1/MKP-1 was con-
stitutively expressed, siRNA knockdown increased cisplatin sensitivity
some 10 fold, reduced the growth of these cell lines in nude mice and
rendered the resulting tumours cisplatin sensitive [63]. In lung cancer
patients dexamethasone is also often co-administered with cisplatin to
ameliorate the undesirable side eﬀects of treatment. However, gluco-
corticoids are known to upregulate DUSP1/MKP-1 expression [64] and
not surprisingly dexamethasone eﬀectively suppressed cisplatin-in-
duced apoptosis in a lung adenocarcinoma cell line indicating that
DUSP1/MKP-1 plays a key role in this potentially undesirable drug-drug
interaction [65]. The role of DUSP1/MKP-1 in mediating resistance to
chemotherapy appears not to be restricted to cisplatin, as the ability of
this phosphatase to inhibit JNK-mediated apoptosis has also been
Table 3
The involvement of MKPs in metabolic homeostasis.
Group Gene/MKP Evidence implicating functions for MKPs in metabolic homeostasis References
Nuclear, inducible MKPs DUSP1/MKP-1 Whole Body KO:
Resistant to diet-induced obesity. [50]
Protected from the loss of oxidative myoﬁbers in skeletal muscle. [52]
Protected against hepatic steatosis. [53]
Increased energy expenditure. [52]
Liver-speciﬁc KO:
Glucose intolerant & susceptible to diet-induced obesity. [56]
Protected against hepatic steatosis. [56]
Decreased energy expenditure. [56]
Skeletal muscle speciﬁc KO:
Resistant to diet-induced obesity. [57]
Increased energy expenditure & oxidative myoﬁbers. [57]
DUSP2 N/A
DUSP4/MKP-2 N/A
DUSP5 N/A
Cytoplasmic ERK-selective
MKPs
DUSP6/MKP-3 DUSP6/MKP-3 KO mice are resistant to high fat diet (HFD)-induced obesity & hepatosteatosis. [155,156]
DUSP7/MKP-X N/A
DUSP9/MKP-4
DUSP9 is implicated in regulation of the response to insulin and GWAS studies have identiﬁed DUSP9 as a
susceptibility locus for the development of Type-2 diabetes, in multiple ethnicities.
[179,180,182]
Liver-speciﬁc loss of DUSP9/MKP-4 sensitises mice to HFD-induced obesity, hepatosteatosis, liver ﬁbrosis and
inﬂammation.
[181]
JNK/p38-selective MKPs DUSP8 N/A
DUSP10/MKP-5 N/A
DUSP16/MKP-7 N/A
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implicated in the resistance of pancreatic cancer cells to gemcitabine
[66], multidrug resistance in glioblastoma [67], resistance to doxor-
ubicin and taxanes in breast cancer [68] and resistance to the protea-
some inhibitor bortezomib [69].
Finally, a recent paper has implicated DUSP1/MKP-1 in a growth
factor-dependent pathway, which promotes intrinsic resistance to the
tyrosine kinase inhibitors (TKI) used to treat chronic myeloid leukemias
(CML). In mouse pro-B BaF3 cells engineered to express the breakpoint
cluster region (BCR)-Abl tyrosine kinase fusion, which drives CML,
Kesarwani et al. [70] found that DUSP1/MKP-1 along with FBJ osteo-
sarcoma oncogene (Fos) were responsible for resistance to the Abl TKI
inhibitor imatinib (Gleevec). Genetic deletion or pharmacological in-
hibition of Fos and DUSP1/MKP-1 eradicated minimal residual disease
(MRD) in multiple in vivo models as well as in patient-derived mouse
xenografts. Mechanistically, DUSP1/MKP-1 seems to inﬂuence TKI
sensitivity via its ability to suppress p38 MAPK activity and modulate
AP1-dependent transcriptional networks. The latter hypothesis is sup-
ported by the ﬁnding that SB202190, a speciﬁc p38 MAPK inhibitor,
also conferred imatinib resistance. While these results are potentially
exciting, some caution is necessary in the interpretation of the data. BCI
(2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride), the
“speciﬁc” DUSP1 inhibitor used to treat mice and reverse disease in a
retroviral bone marrow transduction transplantation leukemogenesis
model is both highly toxic and relatively non-speciﬁc [71].
2.1.4. DUSP1/MKP-1 function in other tissues
Given the key role that MAPK signalling plays in aspects of brain
development and function it is unsurprising that MKPs have been im-
plicated in the regulation of these processes. Indeed DUSP1/MKP-1
plays important roles in neural cell development, neuronal cell survival
and death, glial cell function and events, which underpin learning and
memory (reviewed in [72]). In terms of pathophysiology, an important
observation was that DUSP1/MKP-1 levels were elevated in the hip-
pocampal region of post-mortem brain from patients who had been
diagnosed with major depressive disorder (MDD) [73]. MDD is char-
acterised by chronic or episodic depression and carries a signiﬁcant
(2–7%) risk of suicide.
Duric et al. [73] found that DUSP1/MKP-1 was also elevated in the
hippocampus of rats exposed to chronic unpredictable stress (CUS) an
eﬀect that was attenuated by treatment with the antidepressant drug
ﬂuoxetine (Prozac) a selective serotonin reuptake inhibitor. Further-
more, adenoviral-mediated expression of DUSP1/MKP-1 in the hippo-
campus caused anhedonia (an inability to experience pleasure), as as-
sessed by a reduced preference for sucrose over water, and these
animals displayed other surrogates of depressive behaviour or help-
lessness such as disturbed feeding and increased immobility in the
forced swim test, all of which were also seen in the CUS exposed rats.
Interestingly, all of the latter endpoints were suppressed in CUS ex-
posed DUSP1−/− mice when compared to wild type controls [73].
Mechanistically, these changes were associated with a reduction in
phospho-ERK1/2 levels in CUS exposed wild type mice, which was not
observed in DUSP1−/− mice. A result, which led the authors to con-
clude that ERK was the relevant DUSP1/MKP-1 target. This ﬁnding is
somewhat surprising in the light of our knowledge that JNK and p38,
but not ERK, are the preferred substrates for this phosphatase [15] and
also conﬂicts with a previous study in which a reduction in hippo-
campal phospho-JNK but not phospho-ERK was observed in rats ex-
posed to CUS [74]. Finally, a recent study has identiﬁed similar changes
in DUSP1/MKP-1 levels in the anterior cingulate cortex (ACC) of mice
exposed to neurophathic pain and CUS, which were again reversed by
ﬂuoxetine [75]. While not shedding new light on the biochemical me-
chanisms involved, this latter study does implicate the regulation of
MAPK signalling by DUSP1/MKP-1 in another brain region tightly as-
sociated with regulating mood-related functions.
With respect to neurodegenerative disorders, DUSP1/MKP-1 has
been reported to mediate neuroprotective eﬀects in both in vitro and in
vivo models of Huntington's disease through its ability to suppress
polyglutamine-expanded huntingtin-induced activation of c-Jun N-
terminal kinases (JNKs) and p38 MAPKs [76]. Finally, by suppressing
p38 MAPK activity, DUSP1/MKP-1 has been reported to protect dopa-
minergic neurons from the toxic eﬀects of 6-hydroxydopamine (6-
OHDA) suggesting that strategies aimed at either increasing MKP-1
expression or activity might be a viable strategy in the treatment of
Parkinson's disease [77].
DUSP1/MKP-1 has also been implicated in muscle regeneration as
DUSP1−/− mice are impaired in their ability to recover from
Table 4
The involvement of MKPs in cancer.
Group Gene/MKP Cancer-related phenotypes References
Nuclear, inducible MKPs DUSP1/MKP-1 Reduced or increased expression noted in a number of tumour types and cancer cell lines. [58–60]
Elevated expression implicated in chemoresistance to a variety of anti-cancer drugs including cisplatin,
gemcitabine, doxyrubicin, taxanes and intrinsic resistance to tyrosine kinase inhibitors.
[63–65,67–70]
DUSP2 Down-regulation in a variety of solid tumours and in acute myeloid leukemia. [88–90]
Frequently mutated in Diﬀuse Large B-Cell lymphoma (DBCL). [91,92]
DUSP4/MKP-2 Reduced or increased expression noted in a number of tumour types and cancer cell lines. [58–60,104]
Often epigenetically silenced in DBCL. Lack of expression is a negative prognostic factor. [105]
Implicated in resistance to doxyrubicin in gastric cancers and to Trastuzumab (anti-Her2 antibody) in Her2+
breast cancers.
[106,107]
DUSP5 Expression often elevated in cancer cell lines harbouring mutant Ras of Raf oncogenes. [123–125]
Epigenetic silencing in gastric and colorectal cancers. [126,127]
Genetic deletion sensitises mice to DMBA/TPA-induced skin carcinogenesis. [128]
Oncogene dependent eﬀects of DUSP5 deletion on cell growth and transformation of mouse embryo
ﬁbroblasts.
[131]
Cytoplasmic ERK-selective
MKPs
DUSP6/MKP-3 Expression often elevated in cancer cell lines harbouring mutant Ras of Raf oncogenes. [125,158,159]
Expression initially elevated and then lost during progression of mutant Kras-driven pancreatic ductal
adenocarcinoma and lung cancers.
[160–163]
Positive correlation between DUSP6/MKP-3 expression and transformation by BCR-Abl and mutant Nras in a
murine model of acute lymphobastic leukemia (ALL).
[164]
Loss of DUSP6/MKP-3 reported to be synthetic lethal with mutant Braf in melanoma cell lines. [165]
Up-regulated in human gliobastoma and papillary thyroid carcinoma where it is associated with a pro-
oncogenic function
[167,168]
DUSP7/MKP-X N/A
DUSP9/MKP-4 N/A
JNK/p38-selective MKPs DUSP8 N/A
DUSP10/MKP-5 N/A
DUSP16/MKP-7 N/A
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experimental muscle injury and, when crossed into a mouse model of
Duchenne's muscular dystrophy (the mdx dystrophin null), they display
exacerbated muscular dystrophinopathy [78]. Interestingly, this is ex-
actly the reciprocal of the phenotype observed after deletion of
DUSP10/MKP-5 (see Section 4.2.2) [79]. More recently, the study of
DUSP1−/−/DUSP10−/− double knockout (DKO) mice revealed a se-
vere impairment in muscle regeneration. Satellite cells, the precursors
of muscle cells, were less proliferative and DKO mice had increased
inﬂammation at sites of injury suggesting that the positive regulation of
myogenesis by DUSP1/MKP-1 is dominant over negative regulation by
DUSP10/MKP-5 [80]. Despite the fact that they share common sub-
strates in JNK and p38 it is clear that these two MKPs regulate distinct
signalling events. This may be related to the fact that while DUSP1/
MKP-1 regulates nuclear MAPK activity, DUSP10/MKP-5 can impinge
on cytosolic signalling and thus the two MKPs may regulate quite dis-
tinct sets of MAPK substrates.
2.2. DUSP2
DUSP2 (also known as PAC-1) was ﬁrst identiﬁed as a mitogen-in-
ducible gene in human T-cells and is most closely related to DUSP1/
MKP-1 and DUSP4/MKP-2, sharing 71% and 68% amino acid identity,
respectively [81]. Mainly expressed in hematopoietic tissue, DUSP2
transcription is induced by activation of the ERK1/2 signalling pathway
[81,82]. When expressed in mammalian cells, DUSP2 favours depho-
sphorylation of ERK1/2 and p38 MAPKs, being less able to inactivate
JNK [83]. Its lack of activity against JNK was later suggested to be a
result of the relative inability of this MAPK to cause catalytic activation
of DUSP2 when compared with ERK2 [84]. In a recent twist, DUSP2
was found to be unique amongst the 10 mammalian MKPs in being able
to bind to and dephosphorylate the “atypical” MAPK kinases ERK3 and
ERK4 [85]. In both ERK3 and 4 the classical T-X-Y motif in the acti-
vation loop is replaced by S-E-G, in which the serine residue is the sole
phospho-acceptor and DUSP2 eﬃciently dephosphorylates this residue
in cultured cells.
2.2.1. DUSP2 in innate and adaptive immunity
DUSP2 expression is restricted to thymus, spleen and lymph nodes.
However, DUSP2−/− mice develop normally and show no abnormal-
ities in the numbers of lymphocytes in blood and bone marrow.
Granulocyte numbers and lymphoid tissue development are also
normal, indicating that DUSP2 is not required for immune system de-
velopment [86,87]. However, using the K/BxN model of inﬂammatory
arthritis, wild type mice injected with arthritogenic K/BxN serum
containing autoantibodies to glucose-6-phosphate isomerase (GPI) de-
veloped peripheral inﬂammatory arthritis within 2 days while DUSP2−/
− mice were protected. Further analysis showed that DUSP2−/− ani-
mals had impaired eﬀector responses such as inﬂammatory mediator
production by macrophages and mast cells and decreased mast cell
survival [86]. Taken together, these results demonstrate an unexpected
role for DUSP2 as a positive mediator of inﬂammation. Puzzlingly, sti-
mulated mast cells and macrophages lacking DUSP2 displayed de-
creased ERK1/2, and p38 MAPK phosphorylation and increased JNK
phosphorylation, which is exactly the opposite of the result predicted
by prior biochemical studies [11,84]. No compensatory changes in the
expression of other MKPs was observed and the authors invoke pathway
crosstalk, postulating that the increase in JNK activity on DUSP2 de-
letion resulted in suppression of ERK activity.
More recently, Lu et al., have studied the role of DUSP2 in T cell
development and diﬀerentiation and found that loss of this phosphatase
has a profound eﬀect on the diﬀerentiation of naive T cells in vitro by
favouring Th17 diﬀerentiation, while inhibiting the production of into
Treg cells [87]. Using the dextran sodium sulfate (DSS)-induced model
of intestinal inﬂammation and colitis, they further show that DUSP2−/
− mice exhibit more severe disease when compared to wild type, as
evidenced by increased mucosal hyperemia and colonic ulceration.
Consistent with the in vitro results, this pathology is accompanied by
higher levels of Th17 cells in DSS-treated DUSP2−/− colon and in-
creased levels of pro-inﬂammatory cytokines including IL-6, IL-17,
TNFα and interleukin-1beta (IL-1β) [87]. Mechanistically, while levels
of phospho-ERK and phospho-p38 were higher in untreated DUSP2−/−
colon compared to wild type, no diﬀerences were seen in DSS-treated
colon from the two genotypes. However, higher levels of phospho-
STAT3 were consistently seen in mice lacking DUSP2 and the authors
hypothesise that this transcription factor is a direct DUSP2 substrate in
vivo. However, as JAK/STAT signalling is potently activated in re-
sponse to IL-6 and this cytokine is overproduced in response to DUSP2
deletion some caution must be attached to this interpretation, parti-
cularly as DUSP2 (like DUSP6/MKP-3 see Section 3.1) undergoes cat-
alytic activation by bound ERK2, implying that its full activity as a
protein phosphatase is dependent on binding to a MAPK substrate [84].
Taken together, these results demonstrate that DUSP2 plays key
roles in both the innate and adaptive immune systems, which have
implications for the initiation and progression of pathology in murine
models of human inﬂammatory disease (Table 2). However, at present
it is unclear whether or not these relate to the direct activity of this
phosphatase in modulating MAPK signalling or may involve other re-
levant targets. Clearly more work is required to reconcile the in vivo
observations with precise molecular mechanism.
2.2.2. DUSP2 in cancer
Thus far DUSP2−/− mice have not been crossed into any of the
commonly used murine cancer models and reports of the involvement
of DUSP2 in cancer are relatively scant (Table 4). Down-regulation of
DUSP2 has been reported in a number of solid tumours, where its ex-
pression level was inversely proportional to that of the hypoxia-in-
ducible transcription factor HIF-1α and its loss seemed to mediate in-
creased ERK activation and chemoresistance in cancer cell lines and to
contribute to colon cancer “stemness” [88,89]. Given its expression in
hematopoietic tissues, there are also a number of studies linking DUSP2
with blood cell cancers. Down-regulation of DUSP2 in acute myeloid
leukemia (AML) is associated with constitutive ERK activation [90],
while recent data from cancer genome sequencing of Diﬀuse Large B-
cell lymphomas (DLBCL), the major form of non-Hodgkin's lymphoma,
reveals that DUSP2 is one of the most frequently mutated genes in this
disease [91,92]. The observation that DUSP2 expression is highly in-
ducible upon stimulation of B-cell lymphoma cell lines suggests that
mutations in DUSP2 may have the potential to modify MAPK signalling
in DLBCL. It will be vital to determine the eﬀects of these mutations on
the localisation or activity of DUSP2 in order to explore the possible
contribution of this phosphatase to the initiation and/or progression of
disease.
2.3. DUSP4/MKP-2
DUSP4/MKP-2 was amongst the very earliest of the MKPs to be
characterised and is most closely related to DUSP1/MKP-1 [93–95],
sharing 58.8% identity at the amino-acid sequence level. Although it is
not as widely studied, DUSP4/MKP-2 shares many features with its
nearest relative including transcriptional regulation in response to
growth factors, an ability to dephosphorylate ERK, JNK and p38 MAPKs
and regulation of DUSP4/MKP-2 protein stability by the phosphoryla-
tion of its C-terminus [11,36,96]. The generation of knockout mice has
now advanced our knowledge of DUSP4/MKP-2 function in a number of
areas.
2.3.1. DUSP4/MKP-2 in innate and adaptive immunity
The earliest reports using the DUSP4−/− mice centred on its pos-
sible function as a regulator of innate immunity and inﬂammation.
BMDMs from DUSP4−/−mice showed increased levels of both JNK and
p38 but not ERK signalling in response to LPS. This correlated with a
potentiation of LPS-stimulated induction of the pro-inﬂammatory
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cytokines, IL-6, IL-12Beta (IL-12p40), TNFα, and also cyclooxygenase-2
(COX-2) derived prostaglandin E2 (PGE2) production [97]. However,
IL-10 was suppressed, as was inducible nitric oxide synthase (iNOS)
expression while arginase-1 levels were increased. The reciprocal
changes in iNOS/arginase-1 levels would tend to suppress nitric oxide
(NO) production as arginase-1 competes with iNOS for the same sub-
strate. Following infection with the intracellular parasite Leishmania
Mexicana, mice lacking DUSP4/MKP-2 were found to be more suscep-
tible to infection, with an increased parasite burden and lesion size and
this was accompanied by a suppression of Th1 and/or increased Th2
responses. The reason for the increased susceptibility to Leishmania
Mexicana infection was due to decreased iNOS and increased expression
and function of arginase-1 rather than any modulation of cytokine
synthesis [97]. Taken together these results suggest that DUSP4/MKP-2
does not display simple functional redundancy with respect to its near
relative, but instead is protective against Leishmania Mexicana infection
due to up-regulation of iNOS and suppression of arginase-1 expression,
thus promoting NO-mediated parasite death. This mechanism was also
found to account for the protective eﬀects of DUSP4/MKP-2 against
Leishmania donovani the causative agent of visceral leishmaniasis [98]
and Toxoplasma gondii, which causes toxoplasmosis [99].
Diﬀerences between DUSP4/MKP-2 and DUSP1/MKP-1 were further
underlined in studies of the response of DUSP4−/− mice to experi-
mental LPS-induced sepsis. The ﬁrst major surprise came with the dis-
covery that, in contrast to mice lacking DUSP1/MKP-1, mice lacking
DUSP4/MKP-2 were more resistant to endotoxic shock and also had
lower levels of circulating IL-1β, IL-6, and TNFα [100]. Furthermore,
LPS-stimulated BMDMs derived from DUSP4−/− mice produced sig-
niﬁcantly less TNFα and IL-10 when compared to wild type cells and
this was associated with increased levels of phosphorylated (active)
ERK, but decreased levels of phospho-JNK and p38 [100]. It is unclear
why there is a discrepancy between these results in LPS-stimulated
BMDMs and those obtained by Al-Mutairi et al. [97], but they went on
to show that elevated ERK2 signalling led to induction of DUSP1/MKP-
1 in the DUSP4−/− macrophages and that this MKP was responsible for
the reduction in JNK and p38 signalling and reduced cytokine pro-
duction [100]. This supports a model in which ERK-mediated cross talk
between MKP-2 and MKP-1 acts to regulate cytokine production in
response to LPS, a view supported by the observation that siRNA
mediated knockdown of DUSP1/MKP-1 increased the production of
TNFα by DUSP4−/− BMDMs [100].
In the adaptive immune system deletion of DUSP4/MKP-2, like
deletion of DUSP1/MKP-1 [33], does not aﬀect thymocyte maturation
and positive selection. Furthermore, no enhanced ERK, JNK, or p38
phosphorylation was observed in either activated or phorbol-12-myr-
istate-13-acetate (PMA)-treated DUSP4−/− T cells [101]. However,
CD4+, but not CD8+, T cells did show higher rates of proliferation
without aﬀecting diﬀerentiated Th1 and Th2 T-cell functions in vivo.
The proliferative change in CD4+ T cells lacking DUSP4/MKP-2 was
associated with increased STAT5 phosphorylation and interleukin 2
receptor alpha (CD25) expression [101]. Subsequent work showed that
DUSP4/MKP-2 decreases both the transcriptional activity and stability
of STAT5 and both in vitro and in vivo data showed that DUSP4/MKP-4
deletion enhanced iTreg and reduced Th17 polarisation while DUSP4-
deﬁcient mice were somewhat more resistant to the induction of au-
toimmune encephalitis [102]. Finally, increased DUSP4/MKP-2 ex-
pression has been implicated in age-dependent defective adaptive im-
munity. Increased expression of DUSP4/MKP-2 in CD4+ memory T
cells from older (> 65 years) individuals inhibits the ERK and JNK-
dependent expression of CD40L and reduces the production of the cy-
tokines interleukin-4 (IL-4) and interleukin-21 (IL-21) by follicular
helper cells, thus impairing T cell-dependent B cell responses [103].
These results suggest that speciﬁc inhibition of DUSP4/MKP-2 activity
might form part of a strategy to combat increased morbidity from in-
fections in the elderly.
Taken together these studies clearly implicate DUSP4/MKP-2 in the
regulation of inmate and adaptive immunity (Table 2). However, de-
spite assumptions that its close relationship with the prototypic MKP
DUSP1/MKP-1 might indicate overlapping or identical functions this
enzyme seems to play a distinct role in regulating immune function. In
macrophages there is some debate as to the eﬀects of DUSP4/MKP-2
deletion on the activity of speciﬁc MAPK isoforms with discordant re-
sults in LPS-treated BMDMs [97,100]. In T cells it seems to mediate its
eﬀects via modulation of STAT5 and, as no perturbation in MAPK sig-
nalling was observed in cells lacking DUSP4/MKP-2, this has been taken
as evidence of a MAPK-independent function for this enzyme
[101,102].
2.3.2. DUSP4/MKP-2 in cancer
Although less well studied than DUSP1/MKP-1, there have never-
theless been numerous reports of either increased or reduced expression
of DUSP4/MKP-2 in a wide variety of human cancer cell lines and
primary tumours including pancreatic, lung, ovarian, breast, liver,
thyroid and colon (reviewed in [60,104]). However the majority of
these studies have relied on either association and/or correlation with
clinical outcome/tumour subtype or ectopic expression of this MKP in
cancer cell lines. Thus far the DUSP4−/− knockout mice have not been
crossed into or utilised in any of the well-characterised murine cancer
models and there is no direct evidence of a role for DUSP4/MKP-2 in the
initiation or progression of tumours. Furthermore, the fact that DUSP4/
MKP-2 has a proven role in immune regulation indicates that a con-
ditionally targeted allele of DUSP4/MKP-2 would be required to avoid
the confounding eﬀects of deleting this MKP in immune cells on any
cancer phenotypes observed.
Despite this there have been some recent reports that indicate a role
for this MKP in human cancers (Table 4). DUSP4/MKP-4 was found to
be epigenetically silenced in some 75% of>200 cases of diﬀuse B cell
lymphoma (DBCL) and a lack of DUSP4/MKP-2 was a negative prog-
nostic factor in three independent cohorts of DBCL patients. Mechan-
istically, this cancer appears to be dependent on JNK signalling for
continued survival and loss of DUSP4/MKP-2 contributes to cancer
progression by augmenting JNK activity. This is consistent with the
results of ectopic expression of DUSP4/MKP-2, which ablates JNK ac-
tivity and induces apoptosis in DBCL cells while dominant negative
interference with JNK also restricts survival [105]. There are also in-
dications that DUSP2/MKP-4 is implicated in resistance to che-
motherapy in both gastric cancer, where resistance to doxorubicin is
associated with DUSP4/MKP-2 driven epithelial-mesenchymal transi-
tion (EMT) [106] and in Her2 positive breast cancer where DUSP4/
MKP-2 is associated with resistance to the anti-Her2 humanised
monoclonal antibody Trastuzumab and siRNA mediated silencing of
DUSP4/MKP-2 re-sensitised breast cancer cell lines with an ampliﬁed
Her2 oncogene to this agent [107].
2.3.3. DUSP4/MKP-2 in other tissues
DUSP4/MKP-2 is expressed at increasing levels during the process of
neuronal diﬀerentiation in neural progenitors derived from retinoic
acid (RA)-treated murine embryonic stem cells (mESCs) and lentiviral
DUSP4/MKP-2 siRNA knockdown signiﬁcantly retarded this process.
Importantly, this phenotype could be rescued with siRNA-resistant wild
type but not a catalytically inactive mutant of DUSP4/MKP-2 and loss of
DUSP4/MKP-2 resulted in increased levels of phospho-ERK, but not
JNK or p38 MAPKs, indicating that this is the relevant target. Overall
this data indicates that DUSP4/MKP-2 plays a role in both the neural
commitment of mESCs and neuronal diﬀerentiation and may point to a
wider role for this MKP in brain function and pathology [108]. More
recently direct evidence of a role for DUSP4/MKP-2 in the brain has
come from a study of hippocampal neuronal excitability, synaptic
plasticity and behaviour in DUSP4−/− mice. Long-term potentiation
(LTP) was found to be impaired in MKP-2−/− mice and the frequency
of excitatory postsynaptic current (EPSC) was also increased in both
hippocampal slices and hippocampal cultures. Finally, whereas
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locomotor activity and anxiety-like behaviour were normal in DUSP4−/
−mice, hippocampal-dependent spatial reference and working memory
were both somewhat impaired [109]. Surprisingly, given the estab-
lished role of ERK signalling in LTP [110] no abnormalities in ERK
signalling were observed in either DUSP4−/− brain tissue or in primary
hippocampal cultures. However, JNK or p38 activation was not studied
and the former also play a role in memory formation and synaptic
plasticity [111].
2.4. DUSP5
DUSP5 was ﬁrst identiﬁed as a growth factor and heat shock-in-
ducible nuclear MKP and is closely related to both DUSP1/MKP-1 and
DUSP2/MKP-4 [112–114]. Despite its early discovery and character-
isation as an MKP, little attention was paid to DUSP5, presumably on
the assumption that it would share many of the properties of its nearest
relatives with respect to a broad activity towards ERK, JNK and 38
MAPKs. However, it was later shown that DUSP5 is unique amongst the
four inducible nuclear MKPs in being absolutely speciﬁc for ERK1/2
[115]. Furthermore, growth factor-inducible expression of DUSP5 is
mediated by ERK activity making it a classical negative feedback reg-
ulator of this signalling pathway [116] and DUSP5 binds tightly to its
substrate and is able to anchor inactive ERK in the cell nucleus [115].
Together, these properties deﬁne DUSP5 as the nuclear counterpart of
the inducible cytoplasmic ERK speciﬁc phosphatase DUSP6/MKP-3 (see
Section 3.1).
2.4.1. DUSP5 in innate and adaptive immunity
An early indication that DUSP5might play a role adaptive immunity
came with the observation that it was highly induced following IL-2
stimulation of T-cells [117]. This idea was seemingly reinforced by the
ﬁnding that transgenic expression of DUSP5 in lymphoid cells arrested
thymocyte development at the CD4+/CD8+ (double positive) stage
and caused autoimmune symptoms in these animals [118]. However,
these results illustrate the limitations of overexpression experiments
and probably reﬂect the function of ERK itself, rather than endogenous
DUSP5 in regulating immune cell development. This has been con-
ﬁrmed by more recent experiments utilising DUSP5−/− mice where
global deletion had no eﬀect on innate or adaptive immune cell num-
bers in the bone marrow, spleen or lymph nodes under homeostatic
conditions [119]. However, subjecting DUSP5−/− mice to acute im-
mune challenges has revealed more subtle phenotypes that are modu-
lated in a DUSP5-dependent manner (Table 2).
Thus DUSP5 has been shown to be highly expressed in eosinophils
where it negatively regulates IL-33 mediated survival, via the suppression
of interleukin-33 (IL-33)-induced ERK-activity and down-regulation of
the anti-apoptotic protein B-cell lymphoma-extra large (BCLxL).
Consequently, DUSP5−/− mice challenged by helminth infection display
prolonged eosinophil survival, enhanced eosinophil eﬀector functions
and were able to clear their parasite burden more eﬃciently following
infection [119]. More recently Kutty et al., while conﬁrming that T cell
development is normal in DUSP5−/− mice, have shown that in response
to acute infection with lymphocytic choriomeningitis virus (LCMV) these
animals have decreased numbers of short-lived eﬀector cells (SLECs) and
increased proportions of memory precursor eﬀector cells (MPECs). Both
cell types are derived from eﬀector CD8+ T cells in response to acute
infection with SLEC being highly cytotoxic, cells that readily undergo
apoptosis while MPECs retain the ability to proliferate and eventually
develop into mature memory T-cells. This defect was intrinsic to T cells
as bone marrow chimeric mice in which CD8+T cells were recon-
stituted from DUSP5−/− donors showed an identical phenotype [120]
and this study clearly indicates that DUSP5 plays an essential role in
regulating the survival of SLECs. However, the precise mechanism(s) by
which DUSP5 aﬀects the balance of diﬀerentiating and maintaining SLEC
and MPEC populations and its dependence on ERK activity are as yet
uncertain [120].
2.4.2. DUSP5 and cancer
The canonical Ras-ERK MAPK signalling pathway is frequently de-
regulated in human cancers with activating mutations found in up-
stream components of the pathway including receptor tyrosine kinases
(RTKs), Ras GTPases, the MAPK kinase kinase Braf and MAPK kinase
(MEK) [121]. The observation that Braf is mutated in 40–60% of ma-
lignant melanomas and in tumours of the thyroid, colon and lung un-
derscores the importance of the Ras-ERK pathway in malignant disease,
making it an intense focus of anticancer drug discovery [122]. In
common with the cytoplasmic ERK-speciﬁc phosphatase DUSP6/MKP-3
(see Section 3.1.3), elevated DUSP5 expression is observed in a range of
Ras or Braf mutant cancer cells [123–125] where it is presumed to
suppress oncogenic ERK activation. DUSP5 has also been reported to be
subject to epigenetic silencing in gastric cancers and this correlated
with poorer patient survival [126]. More recently, DUSP5 down-reg-
ulation and promoter hypermethylation has been identiﬁed in color-
ectal tumour samples and cell lines. However, DUSP5 knockdown in
colorectal cancer cell lines displayed limited eﬀects on phospho-ERK
levels and did not increase proliferation. Furthermore, a transgenic
mouse overexpressing DUSP5 in the intestinal epithelium displayed no
alterations in ERK signalling, intestinal homeostasis or adenoma for-
mation and the authors concluded that DUSP5 does not regulate in-
testinal development or tumourigenesis [127]. Although surprising,
given the demonstrable eﬀects of DUSP5 overexpression on ERK acti-
vation in vitro, these results should be interpreted with a degree of
caution as the constitutive transgene used here cannot recapitulate the
transcriptional dynamics inherent in feedback control exerted by en-
dogenous DUSP5.
In contrast Rushworth et al. demonstrated that DUSP5 loss sensi-
tised mice to HRasQ61L-driven skin papilloma formation in the well-
established DMBA/TPA (7,12-dimethylbenz[a]anthracene/12-O-tetra-
decanoylphorbol-13-acetate)-inducible skin carcinogenesis model.
Furthermore, in vitro experiments in DUSP5−/− MEFs revealed an es-
sential non-redundant function for this MKP in suppressing nuclear ERK
activity following acute pathway stimulation. Loss of DUSP5−/− also
provoked the upregulation of a cohort of ERK-dependent genes in-
cluding SerpinB2 in TPA stimulated MEFs [128]. SerpinB2 had pre-
viously been identiﬁed as a susceptibility gene in this model of skin
carcinogenesis [129,130] and concomitant deletion of SerpinB2 re-
versed the sensitivity of DUSP5−/− mice to DMBA/TPA-induced pa-
pilloma formation identifying DUSP5 as a bona ﬁde tumour suppressor
by virtue of its ability to suppress SerpinB2 expression in this animal
model of Ras-induced cancer [128]. More recently, experiments using
wild type and DUSP5−/− MEFs have demonstrated that DUSP5 func-
tion is dependent on the nature of the oncogenic driver. Thus while loss
of this MKP in the context of mutant Ras is compatible with continued
cell proliferation, its deletion in cells expressing mutant BRafV600E
causes ERK-dependent cell cycle arrest and senescence and prevents cell
transformation by this oncogene in vitro [131]. This latter study sup-
ports the idea that MKPs might either suppress or promote carcino-
genesis depending on the oncogenic and tissue context (Fig. 4, Table 4)
and it will be interesting to see the results of DUSP5 ablation in other,
more clinically relevant, murine models of Ras- and Braf-driven cancer.
2.4.3. DUSP5 in other tissues
DUSP5 is implicated in cardiovascular development, where it is
expressed in angioblasts and mature vasculature in zebraﬁsh and
DUSP5 knockdown increased the etsrp+ (ets1-related protein) angio-
blast population during early embryonic development. DUSP5 over-
expression also antagonised the function of a serine threonine kinase,
Snrk-1, which promotes angioblast development [132]. DUSP5 has also
been shown to act as a regulator of cardiac ﬁbroblast proliferation and
cardiac hypertrophy. Ferguson et al., demonstrated that the anti-hy-
pertrophic activity of class I histone deacetylase (HDAC) inhibitors is
mediated by their ability to increase DUSP5 gene expression, thus in-
hibiting both ERK activity and cardiac myocyte proliferation. Ectopic
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DUSP5 expression phenocopied the eﬀects of HDAC inhibition while
DUSP5 knockdown rescued endogenous phospho-ERK levels following
HDAC inhibition [133]. A subsequent study has revealed that HDAC3
speciﬁc inhibitors also induce DUSP5 expression in mouse models of
diabetic cardiomyopathy and that this is associated with reduced hy-
pertrophy and ﬁbrosis [134]. DUSP5 expression is also suppressed by
another epigenetic regulator Methyl-CpG-binding protein 2 (MeCP2)
and high MeCP2 expression was associated with cardiac ﬁbrosis and
MeCP2 knockdown in cardiac ﬁbroblasts, increased DUSP5 expression
and reduced both ERK activity and proliferation [135]. Finally, in adult
rats DUSP5 deletion has been shown to modulate the myogenic re-
sponse of cerebral arteries and autoregulation of cerebral blood ﬂow,
indicating that DUSP5 also plays a physiological role in vascular re-
activity [136].
3. The cytoplasmic ERK-speciﬁc MKPs
3.1. DUSP6/MKP-3
First characterised as an inducible cytoplasmic MKP, which is pro-
totypic of a subfamily of 3 highly related enzymes, DUSP6/MKP-3 was
subsequently found to display absolute substrate speciﬁcity for ERK1
and ERK2 having no signiﬁcant activity towards JNK, p38 or ERK5
[12,137–140]. This selectivity is mediated by high aﬃnity binding of
ERK to the KIM within the amino-terminal domain of DUSP6/MKP-3
and underpinned by catalytic activation of DUSP6/MKP-3 involving a
conformational change within the PTPase domain that repositions key
active site residues and greatly increases enzyme activity [141,142].
The cytoplasmic localisation of DUSP6/MKP-3 is mediated by a leucine-
rich nuclear export signal (NES) within the amino terminal domain and
the tight binding of ERK to the KIM also indicates a role for this MKP as
a cytoplasmic anchor for inactive ERK [143]. Studies of the pattern of
DUSP6/MKP-3 expression during early mouse development established
a link with sites of ﬁbroblast growth factor (FGF) signalling [144] and
subsequent work in the chicken embryo, DUSP6−/− mice and cultured
cells established that DUSP6/MKP-3 is transcriptionally induced in re-
sponse to FGF-mediated ERK signalling and acts as a classical negative
feedback regulator of ERK activity during early development
[145–149].
3.1.1. DUSP6/MKP-3 in immunity and inﬂammation
Relatively few studies have addressed a role for DUSP6/MKP-3 in
immune regulation. DUSP6−/− mice are reported to be indistinguish-
able from their wild type littermates in terms of the total number of
cells and proportions of CD4+, CD8+, and CD4/CD8 double-positive
cells in spleen, mesenchymal lymph nodes (MLN) and thymus [150].
However, T cell receptor (TCR) stimulation of DUSP6−/− CD4+ T cells
resulted in higher levels of phospho-ERK1/2, but not of JNK or p38 and
anti-CD3/28 stimulated CD4+ T cells harvested from spleen and MLN
produced higher amounts of IFN-γ and lower amounts of IL-17A when
compared to wild type controls. Activated DUSP6−/− CD4+ T cells also
displayed increased proliferation in vitro, but this was accompanied by
increased levels of activation-induced cell death (AICD), perhaps ex-
plaining why lymphoid cellularity remains unchanged. In DUSP6−/−
CD8+ T cells the expression of CD107a or lysosomal associated mem-
brane protein 1; (LAMP-1) a marker of lymphocyte degranulation, was
reduced suggesting that DUSP6/MKP-3 may also regulate the cytotoxic
activity of CD8+ T cells.
The changes in cytokine production by CD4+ T cells after DUSP6/
MKP-3 deletion are suggestive of a role in T cell polarisation. When
subjected to Th1 polarizing conditions a larger number of DUSP6−/−
CD4+ T cells produced IFN-γ, while under Th17 polarizing, conditions
DUSP6−/− CD4+ T cells gave rise to fewer IL-17A producing cells.
Taken together these results indicate that DUSP6/MKP-3 regulates the
polarisation of CD4+ T cell subsets by inhibiting Th1 diﬀerentiation
and favouring Th17 diﬀerentiation. Furthermore, to assess the function
of DUSP6−/− regulatory T cells (Treg) these were isolated and co-cul-
tured with naïve CD4+ T cells from WT mice and stimulated with anti-
CD3/CD28 for 72 h before assessing CD4+ T cell proliferation.
DUSP6−/− Treg cells consistently showed a lower capacity to inhibit
the proliferation of naïve CD4+ T cells indicating that DUSP6/MKP-3 is
required for suppressive Treg function.
Finally, to assess DUSP6/MKP-3 function in vivo DUSP6−/− mice
were crossed with IL-10−/− mice and assessed for the development of
intestinal colitis. The double knockout (DKO) mice consistently devel-
oped severe inﬂammation with epithelial crypt hyperplasia, loss of
goblet cells, and immune cell inﬁltration into colonic connective tissue
while DKO colonic explants produced increased levels of IFN-γ and
TNFα, but lower levels of IL-17A when compared to IL-10−/− tissues.
Satisfyingly, administration of PD0325901, a speciﬁc MEK inhibitor,
both ameliorated and reversed the inﬂammatory phenotype seen in the
DKO mice demonstrating that this is a direct result of increased levels of
ERK1/2 signalling in the absence of DUSP6/MKP-3 [150].
In a recent study of the role of DUSP6 in endothelial cell in-
ﬂammation Hsu et al. found that tail vein injection of TNFα caused
elevated expression of Intercellular Adhesion Molecule 1 (ICAM1) in
wild type but not DUSP6−/− animals, suggesting that DUSP6 would
modulate neutrophil recruitment and transendothelial migration at
sites of acute inﬂammation. In agreement with this hypothesis,
DUSP6−/− animals injected intraperitoneally with either TNFα or LPS
showed lower levels of pulmonary neutrophil inﬁltration and lung in-
jury and adoptive transfer of wild type neutrophils into DUSP6−/−
Fig. 4. The eﬀects of DUSP5 deletion on oncogenic signalling through the Ras-ERK
pathway may depend on the nature of the driving oncogene. Deletion of DUSP5 in
cells harbouring mutant HrasQ61L causes elevated nuclear ERK activity. This is
associated with changes in gene expression and an increased susceptibility to
Hras-driven skin carcinogenesis identifying DUSP5 as a tumour suppressor. In
contrast, in MEFs expressing mutant BrafV600E deletion of DUSP5 causes a much
stronger ERK activation that is associated with senescence, growth arrest and
suppression of cell transformation indicating that in cancers driven by activated
Braf DUSP5 may be essential for cancer cell survival.
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mice revealed that the defect was intrinsic to endothelial cells [151].
Surprisingly, in vitro experiments in primary human umbilical vein
endothelial cells (HUVECs) revealed that the role of DUSP6/MKP-3 in
regulating TNFα-induced expression of ICAM1 involved activation of
canonical nuclear factor (NF)-κB but was not dependent on its ability to
dephosphorylate ERK MAPK [151].
Taken together, these studies indicate that DUSP6/MKP-3 may play
complex and tissue speciﬁc roles in immune cell function and in-
ﬂammatory processes (Table 2) and further work will be required to
delineate the precise nature of the signalling events involved and the
tissue speciﬁcity of DUSP6/MKP-3 functions.
3.1.2. DUSP6/MKP-3 in metabolic homeostasis
The ﬁrst indication that DUSP6/MKP-3 might be involved in me-
tabolic control was the ﬁnding that its expression was able to prevent
the suppression of phosphoenolpyruvate carboxylase (PEPCK) gene
expression by insulin. DUSP6/MKP-3 was also expressed in insulin-re-
sponsive tissues and expression levels were markedly elevated in the
livers of insulin-resistant genetically obese (db/db) mice [152]. Sub-
sequent work showed that expression of DUSP6/MKP-3 is also in-
creased in the livers of HFD-induced obese mice and that adenovirus-
mediated DUSP6/MKP-3 expression in lean mice promoted gluconeo-
genesis and increased levels of fasting blood glucose. In contrast, shRNA
knockdown of DUSP6/MKP-3 in both lean and obese mice resulted in
decreased fasting blood glucose levels [153]. Mechanistically the
transcriptional upregulation of gluconeogenic genes such as PEPCK that
underpinned these eﬀects was mediated by the dephosphorylation and
nuclear translocation of Forkhead box protein O1 (FOXO1). Surpris-
ingly, the eﬀects of DUSP6/MKP-3 on FOXO1 were postulated to be
direct, via protein-protein interaction and dephosphorylation of this
transcription factor [154]. However, this ﬁnding is extremely diﬃcult
to reconcile with the known biochemical properties of DUSP6/MKP-3
and in particular the requirement for ERK2 binding to achieve catalytic
activation of this phosphatase [141].
Experiments utilising DUSP6−/− mice to study metabolism have
now been performed with the ﬁnding that mice lacking DUSP6/MKP-3
are somewhat protected from diet-induced obesity (Table 3). However,
quite diﬀerent conclusions were reached regarding the underlying
mechanism. Feng et al. reported that DUSP6−/− mice are protected
against both HFD-induced weight gain and hepatosteatosis and that
these eﬀects were accompanied by reduced liver Triglyceride (TG) le-
vels and adiposity. DUSP6−/− mice also exhibited increased energy
expenditure, enhanced peripheral glucose disposal, and improved sys-
temic insulin sensitivity [155]. Phosphoproteomic analyses in cultured
Hepa1–6 cells +/− siRNAs targeting DUSP6/MKP-3 and comparing
liver lysates from DUSP6−/− and DUSP6+/+ mice revealed signiﬁcant
increases in the phosphorylation of HDAC1 and 2. Pharmacological
inhibition or combined knockdown of these enzymes in primary he-
patocytes from DUSP6−/− mice was able to reverse the protective ef-
fects of DUSP6/MKP-3 deletion by raising the expression levels of
several lipogenic genes, indicating that these enzymes may be the re-
levant in vivo targets [155].
Ruan et al. also reported protection against HFD-induced weight
gain in DUSP6−/− mice together with improved glucose tolerance,
increased insulin sensitivity and protection against hepatosteatosis
[156]. However, faecal transplantation from HFD-fed DUSP6−/− mice
into germ-free animals phenocopied this resistance and following stu-
dies of DUSP6/MKP-3-dependant changes in gut microbiota, intestinal
barrier function and the gut transcriptome they concluded that DUSP6/
MKP-3 loss protects the intestinal epithelial barrier from HFD-induced
interruption and subsequent remodelling of the gut ﬂora to maintain a
lean-associated microﬂora. They conclude that DUSP6/MKP-3 regulates
homeostasis between the gut epithelium, mucosal immunity and mi-
crobiota [156]. In contrast, a recent study observed comparable body
weight, fat and lean mass in DUSP6−/− and DUSP6+/+ mice after
26 weeks on a HFD. However, glucose tolerance was somewhat
abnormal in both lean and obese DUSP6−/− mice when compared to
controls [157]. At present it is unclear why there is a discrepancy be-
tween the latter study and the previous two, but the ﬁnding that var-
iations in the gut microbiota can have profound consequences for
sensitivity to HFD coupled with diﬀerences in the genetic backgrounds
used in these studies (pure C57Bl/6 J vs. mixed 129 x C57Bl/6 J) may
account for this. As was the case for studies of DUSP1/MKP-1, the use of
an unconditional (whole body) knockout of DUSP6/MKP-3 also makes
the interpretation of these studies more diﬃcult and future experiments
using conditional ablation of DUSP6/MKP-3, will be required to address
complexity and tissue speciﬁc interplay in the regulation of metabolic
homeostasis by this phosphatase.
3.1.3. DUSP6/MKP-3 and cancer
Given the direct involvement of Ras/ERK signalling in human
cancer a possible role for DUSP6/MKP-3 has been explored in some
depth (Table 4). As was the case for the inducible nuclear ERK-speciﬁc
phosphatase DUSP5, increased DUSP6/MKP-3 expression has been ob-
served in primary tumours and cancer cell lines, which harbor muta-
tions in either Ras or Braf, where its role as a negative feedback reg-
ulator of ERK activity has led to the suggestion that it may act as a
tumour suppressor [125,158,159]. Thus DUSP6 expression is initially
elevated and then epigenetically silenced during the progression of
mutant Kras-driven pancreatic ductal adenocarcinoma, with the lowest
levels detected in the most invasive and poorly diﬀerentiated tumours
[160–162]. In a similar vein, loss of DUSP6/MKP-3 expression in mu-
tant Kras-driven lung tumours is associated with increased disease se-
verity and histological grade and loss of heterozygosity at the DUSP6
locus occurs in almost 20% of patients [163]. However, as is the case
for many MKPs much of the mechanistic data obtained so far involves
the reversal of cancer-associated phenotypes by ectopic expression of
DUSP6/MKP-3 in cancer cell lines [161,163] and must therefore be
treated with a degree of caution. No direct evidence of a tumour sup-
pressor function for this MKP has yet been obtained by crossing
DUSP6−/− mice into established murine cancer models. In contrast,
two recent reports contain evidence that DUSP6/MKP-3 may actually
be an oncogenic driver in certain human cancers.
Firstly, Shojaee et al., found that the acute oncogenic activation of
BCR-Abl and NrasG12D in human pre-B cells was invariably lethal.
However, any surviving cells were transformed and displayed increased
expression of negative regulators of ERK signalling including DUSP6/
MKP-3. Furthermore, this upregulation of DUSP6/MKP-3 was also seen
in pre-B ALL cells, where it was driven by both Abl and ERK activity and
high DUSP6/MKP-3 mRNA levels in patients with Philadelphia chro-
mosome positive (Ph+) (BRC-Abl-driven) ALL was associated with
shorter survival [164]. To gain mechanistic insight, Shojaee et al.
transformed bone marrow-derived B cell lineage progenitor cells from
DUSP6−/− mice and wild-type controls with BCR-Abl1. Interestingly,
the survival of the DUSP6−/− cells was signiﬁcantly reduced and
conditional expression of NrasG12D in pre-B cells was only able to
transform wild type but not DUSP6−/− cells. siRNA-mediated knock-
down of DUSP6/MKP-3 in human pre-B ALL cells also reduced survival.
All of these observations strongly indicate that pre-B ALL cells are de-
pendent on DUSP6/MKP-3-mediated negative feedback control of ERK
signalling for continued survival and growth [164]. In support of this
conclusion, BCI, a compound identiﬁed as an allosteric inhibitor of
DUSP6/MKP-3, caused a rapid increase in ERK activity in patient-de-
rived Ph+ ALL cells. Mouse xenograft experiments using Ph+ ALL cells
derived from patients after relapse during ongoing therapy with the Abl
inhibitor Imatinib (Gleevec) showed these to be resistant to tyrosine
kinase inhibition, but sensitive to treatment with BCI, indicating that
this drug might be used to treat TKI-resistant Ph+ ALL [164]. While
these results are very provocative, they must be treated with a degree of
caution in that BCI, as mentioned previously in the context of its use as
an inhibitor of DUSP1/MKP-1, is known to be relatively non-speciﬁc
and displays considerable oﬀ-target toxicity [71].
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In a recent genetic screen Wittig-Blaich et al., identiﬁed DUSP6/
MKP-3 amongst a set of genes with growth suppressive properties
consistent with tumour suppressor function. However, speciﬁcally in
the context of mutant Braf–driven melanoma they found that siRNA-
mediated knockdown of DUSP6/MKP-3 caused apoptosis. They spec-
ulate that DUSP6/MKP-3 might be required to prevent BrafV600E hy-
peractivation from triggering cell death via ERK1/2 downstream sub-
strates and suggest that it might represent a synthetic lethal drug target
in this subset of melanoma patients [165]. The idea that MKPs can
intervene to prevent the engagement of tumour suppressive pathways
has been suggested previously, mainly in the context of ERK-dependent
oncogene-induced senescence (OIS) [166] and, as discussed previously,
there is some support for diﬀerential outcomes in terms of cell pro-
liferation and senescence after deletion of the inducible nuclear ERK-
speciﬁc MKP DUSP5 in cells expressing either activated Ras or Braf
[131]. In support of the idea that DUSP6/MKP-3 may be pro-oncogenic
in certain cancer types DUSP6/MKP-3 is upregulated in human glio-
blastoma cell lines and mouse xenograft experiments showed that tu-
mours arising from glioblastoma cells expressing DUSP6/MKP-3 grew
signiﬁcantly faster than non-expressing controls [167]. The over-
expression of DUSP6/MKP-3 in papillary thyroid carcinoma (PTC) cell
lines is also associated with increased cell migration and invasion
[168].
Finally, although DUSP1/MKP-1 has been widely studied as a
modulator of drug responses in cancer chemotherapy (see Section
2.1.3) less attention has been paid to the ERK-speciﬁc MKPs. However,
Phuchareon et al. recently identiﬁed the down-regulation of DUSP6/
MKP-3 as a contributing factor to the reactivation of Ras-ERK signalling
and drug resistance in epidermal growth factor receptor (EGFR) mutant
lung cancer cell lines exposed to the TKI's geﬁtinib (Iressa) and erlotinib
(Tarceva) [169]. Resistance was mediated by increased ERK-dependent
phosphorylation and degradation of the extra-long isoform of the pro-
apoptotic B-cell lymphoma-2 (Bcl-2) family protein Bim (BimEL) thus
promoting cancer cell survival. Interestingly, DUSP6/MKP-3 down-
regulation has also been implicated in mediating reactivation of Ras-
ERK signalling and drug resistance in lung cancer cells harbouring the
echinoderm microtubule-associated protein-like 4 -anaplastic lym-
phoma kinase (ELM4-ALK) fusion protein exposed to the TKI crizotinib
(Xalkori) [170]. As one of these two driver mutations are present in
almost 20% of non-small cell lung cancers (NSCLC), targeting ERK
signalling in combination with the use of TKI's may be a viable strategy
to forestall or prevent TKI resistance and loss of DUSP6/MKP-3 is
worthy of wider study as a possible ERK-mediated drug resistance
mechanism in other tumour types driven by abnormal tyrosine kinase
activity.
In conclusion it is perhaps no surprise that DUSP6/MKP-3 is im-
plicated in the regulation of oncogenic signalling through the Ras/ERK
pathway and recent work indicates that the eﬀects of altered expression
levels may depend on both the oncogenic background the tissue(s) in-
volved (Table 4). Further studies will be required, preferably using
conditional deletion of this MKP in murine models to dissect out its
precise role in carcinogenesis, particularly given its emerging role in
immune regulation and inﬂammatory processes, both of which may
have a bearing on tumour initiation and development.
3.2. DUSP7/MKP-X
DUSP7/MKP-X most closely related to DUSP6/MKP-3 and shares
many properties, including cytoplasmic localisation, a high degree of
substrate speciﬁcity for the ERK1/2 MAPKs and substrate-induced
catalytic activation [12,137,171] but, in contrast to DUSP6/MKP-3,
almost nothing is known about its physiological function(s) or asso-
ciation with human disease. However, DUSP7/MKP-X was identiﬁed in
an siRNA based phenotypic screen for genes involved in meiotic pro-
gression in mouse oocytes [172] and more recent work has shown that
DUSP7-depleted oocytes either fail or are signiﬁcantly delayed in
resuming meiosis and that cyclin-dependent kinase-1/cyclin B (Cdk1/
CycB) activity drops below the critical level required to reinitiate
meiosis. Once in meiosis DUSP7/MKP-X depleted oocytes also had se-
vere chromosome alignment defects and progressed into anaphase
prematurely [173]. These eﬀects were judged to be secondary to a
failure to dephosphorylate and inhibit protein kinase C isoforms, a
prerequisite for the timely activation of Cdk1/CycB and are likely to be
signiﬁcant as both male and female mice lacking DUSP7/MKP-X have
been reported as viable but infertile (http://www.mousephenotype.
org/data/genes/MGI:2387100). As failure to resume oocyte meiosis is a
contributing factor to female infertility in humans it will be important
to establish whether this signalling pathway is conserved.
3.3. DUSP9/MKP-4
MKP-4, the third member of this group of cytoplasmic phosphatases,
is encoded by the X-linked DUSP9 gene and has properties in common
with DUSP6/MKP-3 and DUSP7/MKP-X, although its substrate speciﬁ-
city is somewhat more relaxed with respect to binding and inactivation
of JNK and p38 MAPKs [141,174,175]. DUSP9/MKP-4 is also somewhat
unusual in that it is not transcriptionally regulated in response to either
growth factor simulation or stress, but instead seems to be con-
stitutively expressed and regulated via phosphorylation of a conserved
serine residue adjacent to the KIM, which abrogates substrate binding
[176]. Unconditional deletion of DUSP9 results in embryonic lethality
due to placental insuﬃciency, but tetraploid rescue experiments de-
monstrated that it is otherwise dispensable for normal embryonic de-
velopment [177]. Information about possible physiological roles for
DUSP9 and links to human disease is relatively scant. Selective ex-
pression of DUSP9 expression in Plasmacytoid dendritic cells (pDCs),
but not conventional dendritic cells (cDCs), suggested a possible role in
determining this phenotype. However, conditional deletion of DUSP9 in
pDCs did not increase ERK activation after TLR9 stimulation and only
weakly aﬀected IFN-β and IL-12Beta (IL-12p40) production by these
cells indicating that this MKP is not essential for the high level pro-
duction of IFN-β, which is characteristic of pDCs [178]. However, re-
cent work now indicates a link between DUSP9/MKP-4 and metabolic
homeostasis (Table 3).
In obese and insulin resistant mouse models DUSP9/MKP-4, protein
levels are reported to be elevated in insulin responsive tissues and ex-
pression of DUSP9/MKP-4 caused increased expression of PEPCK.
Overexpression of DUSP9/MKP-4 in adipocytes also blocked insulin-sti-
mulated glucose uptake, again suggesting that this enzyme antagonises the
eﬀects of insulin in responsive cells and tissues [179]. However, in a stress-
induced in vitro model of insulin resistance and following adenoviral-
mediated overexpression of DUSP9/MKP-4 in the livers of genetically
obese (ob/ob) mice Emanuelli et al. reported that DUSP9/MKP-4 expres-
sion improved glucose intolerance, decreased the expression of gluco-
neogenic genes and reduced hepatic steatosis [180]. Despite these ap-
parently contradictory results, a recent study in which conditional liver-
speciﬁc deletion of DUSP9/MKP-4 was used to study the response to a high
fat diet has demonstrated that loss of DUSP9/MKP-4 in the liver sensitises
animals to hepatic steatosis and inﬂammatory responses and that DUSP9
deﬁciency aggravated high fat, high cholesterol (HFHC)-induced liver ﬁ-
brosis [181]. In this context it will be interesting to compare the eﬀects of
whole body DUSP9 KO and also loss of this MKP in other insulin re-
sponsive tissues as studies of DUSP1/MKP-1 function in metabolic home-
ostasis have revealed that the liver phenotype may not be dominant over
the eﬀects of loss of function in other tissues [50,56,57]. Finally, a genetic
variant mapping near to the DUSP9 gene locus has repeatedly been de-
tected in genome-wide association studies (GWAS) as a risk factor for the
development of Type-2 diabetes across diﬀerent ethnicities in human
populations, further reinforcing a link between DUSP9/MKP-4 and meta-
bolic control [182–184]. The availability of a conditionally targeted allele
for DUSP9 should greatly accelerate future work on the possible role of
this MKP, both in metabolic disease and in other pathologies.
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4. The JNK and p38 speciﬁc MKPs
4.1. DUSP8
Along with DUSP7/MKP-X, DUSP8 is probably the least studied of
the 10 dual-speciﬁcity MKPs and there is virtually nothing known about
its physiological function. Since its identiﬁcation as a gene encoding an
MKP with a translated complex trinucleotide repeat within its coding
region and characterisation of its speciﬁcity for the inactivation of JNK
and p38 MAPKs [138] fewer than 20 papers have been published on
DUSP8 and although targeted mouse ES cells have been generated by
the international mouse phenotyping consortium (IMPC), these have
not yet been exploited to produce a mouse model.
4.2. DUSP10/MKP-5
DUSP10/MKP-5 was ﬁrst characterised as a widely expressed JNK
and p38 speciﬁc MKP, which when expressed in mammalian cells is
found in both the cytoplasm and nucleus [185,186]. One unique feature
of DUSP10/MKP-5 is that it carries an amino-terminal extension of
unknown function, but which may carry signals that specify its sub-
cellular localisation [185].
4.2.1. DUSP10/MKP-5 in immunity and inﬂammation
Along with DUSP1/MKP-1, DUSP10/MKP-5 was one of the ﬁrst
MKPs found to regulate both innate and adaptive immune function.
While development of the myeloid and lymphoid lineages was normal
in mice lacking DUSP10/MKP-5, the DUSP10/MKP-5 gene is inducible
at the transcriptional level in response to TLR signalling and peritoneal
macrophages lacking DUSP10/MKP-5 showed increased production of
the pro-inﬂammatory cytokines IL-6 and TNFα. Consistent with this,
LPS injected DUSP10−/− mice had higher serum levels of TNFα when
compared to wild type controls. Mechanistically, JNK appeared to be
the relevant DUSP10/MKP-5 substrate as elevated levels of phospho-
JNK were observed in both macrophages and T cells derived from
DUSP10−/− mice [187]. However, subsequent experiments have
clearly shown that DUSP10/MKP5 does regulate p38 MAPK activity in
both monocyte/macrophages [188] and neutrophils [189] indicating
that both stress activated MAPK pathways are subject to negative reg-
ulation by DUSP10/MKP-5.
As discussed previously in relation to the function of DUSP1/MKP-1
[35], an important function of the innate immune system is mediated
via professional antigen presenting cells (APC), which activate antigen
speciﬁc T cells, thus bridging the innate and adaptive immune systems
[34]. LPS treated APCs isolated from DUSP10−/− mice exhibited en-
hanced priming of ovalbumin-transgenic OT-I (CD4+) and OT-II
(CD8+) T cells as assessed by increased levels of IL-2 production and T
cell proliferation when compared to wild type APCs. Taken together
these results indicate that DUSP10/MKP-5 plays a non-redundant role
as a negative regulator of the innate immune response [187].
In terms of T cell diﬀerentiation and function DUSP10−/− Th1 and
Th2 cells showed increased JNK activation, but this was lost rapidly on
anti-CD3 re-stimulation, indicating that DUSP10/MKP-5 is not the sole
arbiter of JNK activity in these cells. Activation of CD4+ T cells from
DUSP10−/− mice with anti-CD3 (with or without anti-CD28 co-sti-
mulation) resulted in reduced proliferation when compared to wild
type, indicating that DUSP10/MKP-5 is required for T cell expansion.
However, IFN-γ production by activated Th1 and IL-4 production by
activated Th2 cells lacking DUSP10/MKP-5 were increased, while ac-
tivated eﬀector CD8+ T cells from DUSP10−/− mice produced more
IFN-γ and TNFα than wild type cells [187]. In concordance with these
results, immunisation of DUSP10−/− mice with keyhole limpet hae-
mocyanin (KLH) and re-stimulation ex vivo, resulted in reduced antigen-
driven proliferation of splenic T cells but increased levels of IFN-γ and
IL-4 production conﬁrming the reciprocal role of DUSP10/MKP-5 in
regulating of T-cell clonal expansion and eﬀector T-cell cytokine
expression [187]. Finally, the role of DUSP10/MKP-5 in susceptibility
to infection with LCMV and to MOG-induced EAE was tested. While
DUSP10−/− mice showed little diﬀerence in their initial primary T cell
response to infection or in viral clearance, re-challenge caused im-
mune–mediated death, probably as a result of the markedly elevated
levels of serum TNFα produced by CD4+ and CD8+ T cells. In the EAE
model DUSP10−/− mice exhibited a reduced number of CD4 T cells in
the brain, which correlated with reduced incidence and severity of
disease, indicating that this MKP plays a positive role in the generation
and/or expansion of autoreactive T cells in this autoimmune disease
model [187].
More recent work has explored the role of this MKP in regulating
host responses to inﬂammatory stimuli using a mouse model of local
Shwartzman reaction (LSR). LSR is a delayed vascular injury produced
by sequential subcutaneous injection of LPS and TNFα and DUSP10−/−
mice were found to be much more susceptible to this form of injury.
Mechanistically this was the result of increased p38 MAPK activation in
neutrophils and the production of greatly increased levels of superoxide
anion by the NADPH oxidase complex, thus revealing an essential role
for DUSP10/MKP-5 as a negative regulator of p38-mediated neutrophil
reactive oxygen intermediate (ROI) production, [189]. Interestingly,
p38-mediated cytokine and ROS production by macrophages also ac-
counts for the increased susceptibility of DUSP10−/− mice to en-
dotoxin-induced acute lung injury following intratracheal injection of
LPS, again reinforcing the role of this MKP in protection against in-
ﬂammatory tissue injury [190].
Collectively these studies reveal that DUSP10/MKP-5 like DUSP1/
MKP-1 plays an important role in regulating both innate and adaptive
immune responses (Table 2) and reveals signiﬁcant complexity and
tissue speciﬁcity in its interactions with MAP kinase signalling. This is
illustrated by the observation that while the defect in T cell expansion
seen on loss of DUSP10/MKP-5 is responsible for protection against
EAE, this deﬁcit does not result in a reduction in the numbers of LCMV-
reactive T cells following viral infection, probably because of the
compensatory eﬀects of DUSP10/MKP-5 loss in stimulating APC func-
tion.
4.2.2. DUSP10/MKP-5 function in other tissues
Shi et al. have reported a function for DUSP10/MKP-5 in regulating
muscle stem cell function and muscle regeneration. DUSP10−/− mice had
increased levels of p38 and JNK activation, muscle mass and muscle ﬁbre
size when compared to wild type animals. Furthermore, in response to
muscle injury following injection of cardiotoxin, they display an enhanced
regenerative response associated with early upregulation of JNK and later
of p38 activity. Interestingly, when crossed into the mdx (dystrophin null)
mouse model of Duchenne's muscular dystrophy, the double knockout
animals showed an amelioration of disease manifested by improved ske-
letal muscle morphology, a reduced number of degenerating muscle ﬁbres
and improved contractile function. Mechanistically, this was underpinned
by increased muscle stem cell proliferation and diﬀerentiation, which were
regulated by increased JNK-mediated expression of cyclin D and p38
mediated myogenesis respectively. Finally, despite its function as an im-
mune regulator, these eﬀects of DUSP10/MKP-5 loss appeared to be
completely independent of alterations in immune cell inﬁltration into
damaged muscle [79].
Interestingly, the eﬀects of DUSP10/MKP-5 deletion on myogenesis
appear to be due to two main eﬀects. Firstly, deletion of DUSP10/MKP-
5 increases MAPK-dependent phosphorylation of guanine nucleotide
exchange factor for the Ras-related protein Rab-3A Rab3A (GRAB) at
Serine 169, a site required for secretion of the promyogenic cytokine IL-
6 [191]. Secondly, in the absence of DUSP10/MKP-5 increased JNK and
p38 mediated phosphorylation and activation of STAT3, increases the
expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl2) thus
preventing apoptosis during regenerative myogenesis and also leads to
improved antioxidant defence capacity due to a sustained increase in
catalase expression that protects mitochondrial function [192].
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Finally, a recent study has used DUSP10−/− mice to address the
possible function of this MKP in modulating the development of DSS-
induced intestinal inﬂammation and colitis associated cancer (CAC)
(Table 4). Surprisingly, given the previous ﬁndings that mice lacking
DUSP10/MKP-5 were more sensitive to inﬂammatory tissue damage in
skin and lung [189,190], DSS treated DUSP10−/−mice exhibited lower
levels of intestinal inﬂammation, better intestinal crypt architecture
and lower levels of pro-inﬂammatory cytokine/chemokine expression
than wild type animals. This protection was secondary to improved
intestinal epithelial cell (IEC) barrier function, which serves to separate
luminal contents from the mucosal immune system, as evidenced by
reduced IEC leakage of ﬂuorescein isothiocyanate (FITC)-dextran
[193]. Mechanistically, this was due to increased ERK–mediated ex-
pression of Kruppel like factor-5 (KLF5) a transcription factor which up-
regulates cyclinB expression and promotes IEC proliferation during
intestinal regeneration and wound healing. In accordance with this
increased numbers of proliferating Ki67-positive cells were observed in
the intestinal crypts of DSS-treated DUSP10−/− colon compared with
wild type tissue [193]. Again these results suggest possible tissue spe-
ciﬁc variation in DUSP10/MKP-5 activity towards MAPKs as ERK but
not JNK or p38 activity was aﬀected by DUSP10/MKP-5 loss. Finally,
although protective against DSS-induced inﬂammation, the combined
treatment of DUSP10−/− mice with the mutagen azoxymethane (AOM)
and DSS resulted in an increased incidence of adenomatous polyps of
larger size, which stained positive for Ki67 and β-catenin. Overall, this
strongly suggests that the IEC and the subsequent tumours were more
proliferative in the absence of DUSP10/MKP-5 indicative of a tumour
suppressor function for this MKP, an idea supported by the observation
that higher levels of DUSP10/MKP-5 expression correlated with better
survival amongst patients with colorectal cancer [193].
4.3. DUSP16/MKP-7
DUSP16/MKP-7 was the last of the 10 dual-speciﬁcity MKPs to be
identiﬁed and was characterised as a JNK and p38-speciﬁc MKP with a
possible function as a regulator of JNK activity in macrophages
[194–196]. Although relatively little is known about this phosphatase,
three recent studies using knockout mice have begun to shed some light
on its possible physiological role(s). Firstly, using a gene trap null
mutation Niedzielska et al. reported that loss of DUSP16/MKP-7 caused
perinatal lethality [197]. Observing that DUSP16/MKP-7 was inducible
in macrophages in response to TLR agonists, they used fetal liver cells
from the null mice to reconstitute the lymphoid and myeloid lineages in
lethally irradiated syngeneic CD45.1+ animals. They found that T and
B cell populations were present in the normal numbers, that> 95% of
resident macrophages were derived from the DUSP16/MKP-7 null
donor cells and the mice had normal numbers of granulocytes and
plasmacytoid dentritic cells, indicating that DUSP16/MKP-7 is not es-
sential for homeostasis of the immune system under steady state con-
ditions. However, there was a deﬁcit in numbers of splenic CD11c
+/CD11b+myeloid dendritic cells secondary to impaired granulo-
cyte-macrophage colony-stimulating factor (GM-CSF)-driven prolifera-
tion of bone marrow progenitors [197]. Subjecting reconstituted mice
to LPS challenge revealed no undue sensitivity to sepsis, but did reveal
JNK-dependent overproduction of IL-12Beta (IL-12p40) by macro-
phages in response to LPS [197]. Overall these results reveal a dual
function for DUSP16/MKP-7 in the innate immune system involving
selective control of diﬀerentiation and cytokine production (Table 2),
but further work is required to map out the physiological consequences
of this regulation.
Zhang et al also reported that loss of DUSP16/MKP-7 was lethal and
used reconstitution experiments to study the role of this MKP in
adaptive immunity (Table 2) [198]. In agreement with Niedzielska
et al. [178], they found that T cell development and numbers were
normal, but that CD4+ T cells lacking DUSP16/MKP-7 were hyper-
responsive to activation, produced much more IL-2 and had higher rates
of proliferation when compared to wild type cells. To study T cell dif-
ferentiation and function they cultured naive DUSP16−/− CD4+ T cells
under Th1, Th2, or Th17 conditions in vitro and found that while
functional Th1 and Th2 cells were produced normally, DUSP16−/−
Th17 cell populations produced less IL-17A and IL-17F, and contained
nearly 50% less IL-17A–producing cells compared with WT cells [198].
Interestingly, U0126 a speciﬁc MEK inhibitor, eﬃciently reversed the
deﬁcit in IL-17A producing Th17 cells in vitro, indicating that regulation
of ERK and not JNK or p38 was responsible. Given the role that Th17
cells play in autoimmunity, the susceptibility of the reconstituted ani-
mals was also assessed using the MOG-induced model of EAE and
consistent with the functional Th17 deﬁcit, these animals were less
susceptible to disease indicating an essential role for this MKP in au-
toimmune responses [198].
Finally, a recent study has explored the reason for the embryonic/
prenatal lethality in mice lacking DUSP16/MKP-7 and revealed an es-
sential role for this MKP in brain development. Embryos lacking
DUSP16/MKP-7 exhibited congenital obstructive hydrocephalus to-
gether with brain overgrowth. This was secondary to blockage of the
midbrain aqueduct by the expansion of neural progenitor cells, even-
tually preventing the outﬂow of cerebrospinal ﬂuid. Interestingly only
an increase in cells staining positively for phospho-p38 was observed in
the aﬀected regions of the CNS indicating that this MAPK, rather than
ERK or JNK could be the relevant target [199].
Taken together these studies reveal the ﬁrst essential role for a
member of the MKP family of enzymes in brain development and as the
phenotype of DUSP16−/− mice recapitulates aspects of diﬀerent
human neurodevelopmental disorders suggests that either DUSP16/
MKP-7 or the pathways it regulates may be implicated. They also reveal
speciﬁc defects in innate and adaptive immunity in mice lacking
DUSP16/MKP-7. In particular the speciﬁc role of DUSP16/MKP-7 in
promoting autoimmunity make it a potential therapeutic target in a
range of human disorders such as inﬂammatory bowel disease, rheu-
matoid arthritis and lupus.
5. Conclusions and future perspectives
The past decade has seen an acceleration in the use of GEM models
to probe the physiological and pathophysiological roles of the MKPs
and these have provided a wealth of information for certain members of
the family, particularly in relation to the functional regulation of the
immune system, but also in metabolic disease and cancer. As is the case
for other classes of protein phosphatases, it is abundantly clear that
MKPs are not merely passive “erasers” of protein phosphorylation, but
instead form a complex network of activities in cells and tissues that act
to regulate the spatiotemporal activity of the diﬀerent MAP kinase
pathways and play essential roles in regulating key physiological out-
comes.
Several themes have emerged, one of which is the importance of
compartmentalised regulation of MAPK signalling by activities in the
nucleus and cytoplasm as exempliﬁed by the regulation of nuclear JNK
activity by DUSP1/MKP-1 in metabolic control [50] and nuclear ERK
activity by DUSP5 in cancer [128]. It is also clear that there are both
tissue and cell type speciﬁc diﬀerences in the MAPK isoforms targeted
by particular MKPs, one example being the preference of DUSP1/MKP-1
for inactivation of p38 MAPK in macrophages and dendritic cells
[30,35] whereas JNK is the relevant substrate in T cells [33]. Thus far,
we do not have any detailed grasp of how these speciﬁcities may be
altered in vivo. This must be addressed in future work as must the va-
lidity of putative non-MAPK substrates for certain MKPs invoked in
disease models. The latter include the possibility that STAT3 is directly
targeted by DUSP2 in innate immunity [87], the potential regulation of
FOXO1 and as yet uncharacterised non MAPK substrates by DUSP6/
MKP-3 in metabolic regulation [154] and endothelial inﬂammation
[151] respectively and modulation of PKC activity by DUSP7/MKP-X in
oocyte meiotic progression [173].
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Finally, there are numerous examples where knockout phenotypes
indicate that certain MKPs may be therapeutic targets in human dis-
ease. These include inhibition of DUSP1/MKP-1 in combatting obesity
and depression [50,73] and DUSP2 as a potential anti-inﬂammatory
drug target [86]. However, caution must be exercised here as inhibition
of DUSP1/MKP-1 could also result in more severe inﬂammatory re-
sponses and many existing anti-inﬂammatory agents, such as gluco-
corticoids, actually enhance the expression and activity of this MKP as
part of their mode of action. Clearly speciﬁcity of action towards in-
dividual MKPs would also be crucial in any strategy to target these
enzymes and the avoidance of undesirable side eﬀects. In this regard
and due to the involvement of a redox active cysteine residue in cata-
lysis, the PTPase superfamily has long been regarded as “undruggable”.
However, recent progress in the development of allosteric PTPase in-
hibitors [200,201] gives hope that future work will lead to the devel-
opment of highly speciﬁc small molecules able to target MKP activity,
which will then allow a meaningful exploration of their therapeutic
potential.
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